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Abstract
Tenascin (TN) is a large hexameric glycoprotein which is expressed
transiently in the extracellular matrix at times of tissue development,
proliferation and reorganisation. It is overexpressed in the stroma of
several types of malignant tumours. The expression of TN in ovarian
cancer has not previously been investigated. The aims of the project were
therefore to (i) define the expression of TN in ovarian cancer, (ii) examine
factors controlling its production and (iii) explore the functionality of the
protein.
Initial studies characterised the expression of TN in a series of malignant,
benign and borderline ovarian tumours. TN protein was examined by
immunohistochemical staining of frozen sections of tumours. Malignant
and borderline tumours showed a significantly greater incidence and
intensity of stromal staining as compared to benign tumours. Omental
metastases showed a pattern of protein distribution strikingly similar to
their primary counterpart. These data suggest that TN is overexpressed in
malignant ovarian tumours.
TN exists in a number of different isoforms, which are produced by
alternative splicing of the RNA transcript. The pattern of different
isoforms expressed was investigated using RT-PCR and hybridisation to
specific oligonucleotides. The smallest TN splice variant was found in all
tumours examined while the appearance of larger molecular weight
transcripts was predominantly limited to malignant tumours.
In order to determine which cell types were capable of producing TN, in
vitro, fibroblast cells, cultured from ascitic fluids of ovarian cancer
patients, and established ovarian carcinoma cell lines were studied. TN
levels in conditioned media were measured by ELISA. "Basal" levels of
TN secretion were determined by culturing cells in serum-free media;
under these conditions the ovarian fibroblasts secreted levels of TN over
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100 fold greater than the epithelial cells. RT-PCR data showed that
epithelial and fibroblast cell lines express TN RNA and display multiple
RNA splice forms.
To examine whether a paracrine interaction between the fibroblast and
epithelial cells can influence TN production, the cells were co-cultured in
compartments separated by a filter, which allowed diffusion of soluble
factors. The co-cultured populations of cells produced significantly more
TN than either cell type alone. The effects of a number of potential
modulating factors, on secretion of TN, have been investigated. Several
factors (IGF n, TGFfi, progesterone and EGF) stimulate TN secretion by
fibroblasts while other factors (gonadotrophins and interferon) inhibit
TN secretion in the same cell type. Of the factors studied TGF-fi provided
the greatest induction of TN in fibroblasts. None of these factors induced
the PEOl epithelial cell line to produce measurable levels of TN.
Adhesion and migration assays were used to examine how ovarian
carcinoma cell lines interacted with TN, as compared with the ECM
proteins fibronectin and collagen IV. The assays demonstrated that TN
promoted cell adhesion, spreading and migration in the SKOV-3, 59M,
PEOl and PE04 ovarian carcinoma cell lines, however, fibronectin and
collagen IV appeared to be preferable substrates. Immuno-staining and
analysis by flow cytometry of these cell lines demonstrated that all
expressed the integrin a28lwhich can bind TN, the SKOV-3 cell line also
expressed the integrin aVfi3.
These studies have demonstrated that TN is overexpressed in malignant
ovarian tumours, and paracrine growth factors, such as TGFfi, can induce
the synthesis of TN in ovarian fibroblasts. Tumour cells can adhere to,
and migrate on TN. These data would be consistent with TN playing a
role in the invasion and metastasis of ovarian cancer
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Ovarian cancer, when diagnosed at its earliest stages, is a disease
amenable to treatment, with a five year survival rate of approximately
80% (Young et al., 1993). However, as early stage ovarian cancer is
asymptomatic the disease is rarely detected until it has spread to other
organs (Ozols et al., 1992). Late stage ovarian cancer has a much poorer
prognosis with 5 year survival rates of less than 15%. This accounts for
the disease statistics that mean of the 5000 cases of ovarian cancer which
occur each year in the UK there are 4000 deaths, making ovarian cancer
the most common cause of gynaecological cancer death in women.
1.1.2 Etiology of ovarian cancer
Only 5% of all patients with ovarian cancer come from a family with a
history of the disease (Greene et al., 1984). This suggests that factors in
addition to genetic modifications may induce cancer development in the
ovary.
(i) Environmental factors
Many environmental factors potentially contribute to an increased risk in
ovarian cancer, but no single factor has been identified as causative.
However population studies have strongly suggested that environmental
factors may play a role in the process of ovarian carcinogenesis. For
example the incidence of ovarian cancer in Japan is low, compared with
other industrialised countries.Japanese women who have emigrated to
the USA have an increased incidence compared with Japanese in Japan
(Lingeman, 1974). It has been proposed that this greater incidence may be
due to environmental carcinogens, for example those in the diet.
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Higher risk of ovarian cancer has been reported to be associated with
increased intake of saturated fats (Cramer et al, 1984; Risch et al, 1994).
Risch et al. (1994) also showed that vegetable fibre reduced ovarian cancer
risk. However the involvement of single dietary components is always
difficult to prove and there have been few confirmatory studies.
Other dietary factors have also been examined; increased alcohol
consumption showed no higher risk, while coffee consumption may
confer a small risk increase (Byers et al., 1983). The observation that
increased lactose consumption from milk products may lead to increased
risk (Cramer et al, 1989) is still being investigated.
Talcum Powder, which until recently contained asbestos, had been
suggested to be involved in ovarian carcinogenesis (Longo and Young,
1979), although, more recent studies have failed to confirm this
(Whittemore et al., 1988).
While the link between herpes papilloma virus and cervical cancer has
been well established (Vousden, 1989) there is no evidence for a link
between viral infections and ovarian cancer (Lingeman, 1974).
(ii) Genetic factors
Three heritable forms of ovarian cancer have been defined. Patients with
these hereditary syndromes tend to develop ovarian cancer at a younger
age than the general population. Site-specific ovarian cancer and
hereditary breast/ovarian cancer are rare and appear to be linked mainly
to mutations in the putative tumour suppressor gene BRCA1 (Steichen-
Gersdorf et al, 1994). Lynch syndrome II associates ovarian cancer with a
number of other cancers including colorectal, gastrointestinal and breast
carcinoma. Other heritable cases of ovarian cancer are likely to be due to
mutations in other genes and a second gene linked to breast and ovarian
cancer, BRCA2, has already been identified (Wooster et al, 1994).
While 95% of ovarian tumours are not genetically linked through germ
cells, they are caused by multiple genetic lesions which accumulate in
ovarian surface epithelial cells. Gross chromosomal abnormalities are
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evident in ovarian cancer (Gabra and Smyth, 1996), but whether these
abnormalities are causal is difficult to determine. Damage to the genome
which arises sporadically can be negated by DNA repair mechanisms
(some of which are initiated by tumour suppressor genes e.g. p53);
however if these tumour suppressor genes themselves become damaged
they can no longer programme the repair of any further genetic lesions
which may occur. This further damage may result in the activation of
oncogenes promoting the process of carcinogenesis.
(iii) Hormonal factors.
Fathalla (1971) proposed that whenever the ovaries release an ovum the
damage and proliferative repair processes involved makes the
epithelium susceptible to genetic alteration. Cycles of damage and repair
could lead to cumulative lesions resulting in an increased risk of
development of ovarian cancer. This idea has been referred to as the
incessant ovulation theory.
Circumstantial evidence in support of the incessant ovulation theory
comes from observations that in nulliparous women there is increased
incidence of the disease (Cramer et al, 1983). Increased incidence has also
been associated with women who have an early menarche or late
menopause and are therefore exposed to more ovulatory cycles. The
general increase in ovarian cancer could also be partly explained by the
decreasing parity of women in developed countries; conversely childbirth
seems to confer a protective effect. According to the incessant ovulation
theory this protective effect is a consequence of pregnancy preventing
further ovulation and thus reducing the risk of genetic damage in the
ovary. Other factors which suppress ovulation should therefore also
confer a protective effect against ovarian cancer. In this respect studies
have now shown that the oral contraceptive pill, which prevents
ovulation, can reduce the risk of ovarian cancer by 50%, when taken over
a 5 year period (Hankinson et ah, 1992).
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Other theories of hormonal involvement in the development of ovarian
cancer include the excess gonadotrophin hypothesis. Post-menopausal
women have increased levels of gonadotrophins and this correlates with
the high incidence of ovarian cancer seen in women at the age of
menopause (Stadel, 1975). Additionally, some studies have shown that
women treated with fertility drugs (which contain gonadotrophins and
gonadotrophin stimulating hormones) may have an increased risk of
developing ovarian cancer (Whittemore, 1993). As these drugs
hyperstimulate the ovary this would increase the number of ovulations
and be consistent with the incessant ovulation hypothesis.
(iv) Growth factors and cytokines
The normal ovary undergoes cycles of proliferation and reorganisation
that require tight control, not only by hormones but also in an autocrine
and paracrine nature by peptide growth factors and cytokines (Giordano,
1992). The loss of regulation by these factors, for example, by constitutive
activation of their receptor or over expression of the factor, may give cells
a growth advantage resulting in the progression of initiated tumour cells.
The most widely investigated group of growth factors in ovarian cancer is
the epidermal growth factor (EGF) family (which includes EGF and TGF-
a). These factors bind to the EGF receptor which is a member of the type-1
tyrosine kinase family of receptors. Both TGF-a and EGF have been
shown to stimulate growth of ovarian cancer cells in vitro (Crew et al.,
1992) and the EGF receptor appears to be overexpressed in many ovarian
tumours (Berchuck et al., 1991). Other members of the type-1 tyrosine
kinase family of receptors (including c-erbB-2) are also implicated in
ovarian cancer (Berchuck, 1990).
Insulin-like growth factors I and II (IGF-I and IGF-II) are a pair of growth
factors which have growth stimulatory effects on ovarian cancer cells in
vitro (Bartlett et al., 1995). They also play a role in the normal ovarian
cycle of replication and differentiation (Giordano et al., 1992).
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The transforming growth factor fi (TGF-fi) family exist in 3 isoforms fii, &2
and C3 (Arrick, 1990). These factors interact with serine-threonine kinase-
linked receptors on the cell surface (Massague, 1992). The TGF-fi's have
been shown to inhibit the growth of many ovarian cancer cell lines
(Bartlett et al., 1992; Hurteau et al., 1994). Many ovarian cancer cell lines
and ovarian tumours express all 3 isoforms (Bartlett et al., submitted). It is
likely that TGF-fi exerts paracrine effects on the surrounding stromal cells
(Dickson et al., 1987).
1.1.3 Pathophysiology
Tumours of the ovary can present with a wider variety of
histopathologies than those in other organs; these types have been
classified by the World Health Organisation and are summarised in table
1.1.
Table 1.1 Summary of the WHO classification of malignant ovarian
tumours (Serov and Scully, 1973)
I Common "epithelial" tumours
A. Serous B. Mucinous
C. Endometrioid D. Clear cell
E. Brenner F. Mixed epithelial
G. Undifferentiated H. Unclassified
n Sex cord stromal tumours
ni Lipoid cell tumours
IV Germ cell tumours
V Gonadoblastoma
VI Soft tissue tumours not specific to the ovary
VII Unclassified tumours
VIII Secondary metastatic tumours
IX Tumour-like conditions
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The wide range of types of ovarian tumours reflects the complexity of the
development of the ovary. However the majority of ovarian tumours
(almost 90%) are epithelial in origin, with the remaining tumour types
being rare and generally limited to younger women (Li et al., 1973).
Common "epithelial" tumours develop in the surface epithelium which
is derived from the mesothelium of the embryonic ovary (Fox, 1985).
During embryogenesis this mesothelium forms a structure called the
Mullerian duct which later develops into the main genital duct. The
common epithelial tumours derived from this structure reflect the
various histologies into which the Mullerian epithelium can
differentiate. Thus, serous tumours are similar to fallopian tube
epithelium, endometrioid tumours resemble endometrium and
mucinous tumours resemble endocervical epithelium. Of the epithelial
ovarian cancers approximately 40% are serous, 15% are endometroid and
a further 15% are mucinous (Young et al., 1993). Clear cell tumour types,
which are also similar to the endometrial epithelium constitute only 6%
of the epithelial ovarian tumours. 17% of epithelial ovarian tumours are
undifferentiated and these tumours tend to be very aggressive.
Benign tumours are usually cystic and of serous or mucinous histology
(Ashley, 1990). They can grow to enormous size but do not invade their
underlying stroma. Consequently benign tumours can simply be
removed by surgery and have an excellent prognosis.
A small group of tumours is classified as having borderline malignant
potential. Generally, these tumours are well differentiated, show no
destructive stromal invasion, progress slowly and rarely metastasise. The
term "borderline tumours" was chosen by the WHO; however, FIGO
prefers the designation "carcinoma of low malignant potential". Like
benign tumours, these have an excellent prognosis.
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1.1.4 Stage and grade
The stage at which ovarian cancer is detected is very important to the
outcome of the disease. The stage is determined by the extent of disease at
the time of diagnosis and the most widely used staging classification is
that of the International Federation of Gynaecology and Obstetrics (FIGO)
which is shown in table 1.2 (FIGO Committee, 1986).
The survival of patients is directly correlated with their tumour stage.
The 5 year survival for patients with stage I disease is 80-90%, and patients
with stage II disease also have a good 5 year survival rate (approximately
80%). Patients with later stage disease have a poorer prognosis with 5 year
survival rates of approximately 15% for stage III and less than 5% for
stage IV (Ozols et al., 1992).
In addition to the stage of the cancer being significant, the degree of
histological differentiation of the tumour is of prognostic value. The
grading system in widespread use was originally proposed by Broders in
1926. Grading is based on the percentage of undifferentiated cells in the
tumour section: well differentiated tumours demonstrate very little
cellular atypia (0-25%), moderately differentiated tumours still show a
small degree of histological differentiation but the proportion of
undifferentiated cells is increased. Poorly differentiated tumours may be
totally undifferentiated and are frequently rapid growing and very
aggressive (Day et al., 1975).
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Table 1.2 FIGO stages for primary carcinoma of the ovary
Stage Definition
I Growth limited to the ovaries
IA Growth limited to one ovary; no ascites; no tumour on the
external surface; capsule intact
IB Growth limited to both ovaries; no ascites; no tumour on the
external surface; capsule intact
IC Tumour either stage la or lb but with tumour on surface of one or
both ovaries; or with capsule ruptured; or with ascites present
containing malignant cells or with positive peritoneal washings
II Growth involving one or both ovaries with pelvic extension
IIA Extension and/or metastasis to the uterus and/or tubes
IIB Extension to other pelvic organs
EC Tumour either stage Ha or lib but with tumour on surface of one or
both ovaries; or with capsule ruptured; or with ascites present
containing malignant cells or with positive peritoneal washings
HI Tumour involving one or both ovaries with peritoneal implants
outside the pelvis and /or positive retroperitoneal or inguinal
nodes; superficial liver metastasis; tumour is limited to the true
pelvis but with histologically proven malignant extension to the
small bowel or omentum
IIIA Tumour grossly limited to the true pelvis with negative nodes but
with histologically confirmed microscopic seeding of abdominal
peritoneal surfaces
IIIB Tumour involving one or both ovaries with histologically
confirmed implants of abdominal peritoneal surfaces not
exceeding 2 cm in diameter; nodes are negative
mC Abdominal implants greater than 2 cm in diameter and/or
positive retroperitoneal or inguinal nodes
IV Growth involving one or both ovaries with distant metastases. If
pleural effusion present, there must be positive cytology to assign a
case to stage IV; parenchymal liver metastasis.
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1.1.5 Treatment of ovarian cancer
(i) Surgery
Initial surgery is vital for accurate diagnosis and staging of ovarian cancer,
as the stage of the disease determines the nature of further treatment. In
early stage disease surgery alone may be adequate treatment with no
further therapy being required (Young et al. 1990). Although unlikely to
be curative, primary surgery is often performed in patients with more
advanced stage cancer, as debulking of residual tumour mass not only
increases the patients comfort but may also result in increased survival.
Debulking to less than 2cm improves the chance that the tumour will
respond to adjuvant therapy (Delgado et al. 1984).
(ii) Radiotherapy
Radiotherapy is not frequently used for the treatment of ovarian cancer,
as the entire abdomen requires irradiation and this can result in serious
complications, due to the sensitivity of the liver, kidneys and bowel to
radiation. However this approach may be used in patients with early stage
disease with poor prognostic factors, who have received good debulking
surgery (Ozols et al., 1992).
(iii) Chemotherapy
Ovarian cancer was one of the first solid tumours to be treated with
systemic cytotoxic chemotherapy (Ozols and Young, 1984). Systemic
therapy is now widely accepted as the best treatment for patients whose
ovarian cancer extends beyond the pelvis (stage III and IV). Twenty years
ago the treatment of choice was single alkylating agent therapy, usually
melphalan. Several non-alkylating agents have been found to be active
against ovarian cancer, with cis-diamminedichlorplatinum (cisplatin)
probably being the most active agent for the treatment of ovarian cancer
(Thigpen, 1985). However, cisplatin causes a variety of adverse side effects.
Problems with toxicity of cisplatin led to the development of analogues
such as carboplatin.
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Standard chemotherapy now consists of platinum containing regimens in
combination with other drugs (usually an alkylating agent). These
produce a higher response rate than single agent regimens (Young et al.
1978) but the overall 5 year survival rate of patients remains low. It is
generally believed that this is due to acquired or inherent drug resistance,
and thus new therapies are constantly being sought. One new drug which
has been shown to improve outcome, when used in combination with
platinum, is Taxol. Taxol produces mitotic arrest and is currently being
examined in prospective clinical studies (Einzig et al., 1992; Kavanagh et
al, 1993).
(iv) Immunotherapy
The containment of ovarian cancer within the peritoneal cavity makes it
a suitable target for immunotherapy. To date most studies have utilised
non-specific immunotherapy, often employing cytokines to stimulate the
host's immune response. A few studies have utilised specific monoclonal
antibodies, coupled to cytotoxic moieties, however these can produce
serious side effects. These strategies and other current experimental
therapies, such as genetic manipulation of tumour cells to make them
more immunogenic, are reviewed by Kehoe (1995).
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1.2 Invasion and metastasis
The ability of malignant tumours to spread from their original site and
form secondary tumours in distant tissues presents the greatest obstacle to
successful tumour treatment. The process by which tumour cells invade
and metastasise is a complex multistage set of interactions involving
tumour cells, host cells and extracellular matrix (Aznavoorian et al., 1992;
Liotta et al., 1991). The metastatic process (figure 1.1) begins with the
tumour cells penetrating the epithelial basement membrane and
invading the surrounding stroma. To travel to distant sites the tumour
cells have to then enter either the blood or lymphatic system. Once in
these systems the tumour cells must survive the body's immune
response, arrest in a vascular bed, invade and proliferate in a secondary
tissue to form a new tumour.
The first stages of the metastatic process, involving interactions with the
matrix, can be separated into 3 defined sequential steps, namely
attachment, proteolysis and migration. These stages are discussed
separately in the sections below.
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This figure (adapted from Aznavoorian et al., 1992) illustrates the three-
step hypothesis of invasion. The first step shows a tumour cell in a
capillary attached to the subendothelial membrane. The second stage
involves the cleavage of matrix components by the secretion/activation
of proteinases. Finally the tumour cell migrates into the stroma,
beginning with the protrusion of pseudopodia.
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1.2.1 Tumour cell adhesion
In order to progress the invasive process, tumour cells must first do two
things; (i) detach from neighbouring cells and (ii) form an attachment
with the basement membrane surrounding the tumour. Cell adhesion
molecules such as cadherins, which mediate cell-cell binding, have been
shown to have inhibitory roles in the process of metastasis (Uleminckx et
al., 1991). Some studies looking at adhesion of tumour cells to matrix
proteins, through receptors such as integrins have shown that cells with
strong adhesion to the substrata are less invasive (Giancotti and
Ruoshlahti, 1990). Other investigations have shown that inhibition of
tumour adhesion to matrix proteins also results in less aggressive
invasive behaviour (Aznavoorian et al., 1992). While these results appear
to be contradictory, Aznavoorian et al. (1992) postulated that invasion
may actually require an intermediate level of adhesion to the matrix.
Cells which adhere strongly may never break away from their original
site, while those which are unable to attach to the matrix may not digest
and migrate through the basement membrane, and would not arrest in
and invade a second site.
1.2.2 Proteolysis
The basement membrane is a continuous, dense matrix of protein which
must be breached if tumour cells are to invade. Two to eight hours after
tumour cells have attached to the basement membrane, a localised zone
of lysis is seen in the matrix at the point of tumour cell contact. The main
family of proteolytic enzymes implicated in the process of matrix
dissolution are the matrix metalloproteinases. These enzymes are
secreted in the form of proenzymes which require activation. The family
of matrix metalloproteinases can be divided into 3 groups (Matrisian
1992): the stromelysins, interstitial collagenase and type IV collagenases.
The groups are categorised on the basis of substrate specificity. Interstitial
collagenase degrades fibrillar collagens (Templeton et al., 1990) and the
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type IV collagenases are capable of degrading type IV collagen which is the
major component of basement membrane (Collier et ah, 1988;Hibbs et ah,
1987). The stromelysins, stromelysin-1, stromelysin-2, and matrilysin can
degrade laminin, fibronectin and proteoglycan core proteins (Wilhelm et
ah, 1987). Another member of this family is named stromelysin-3 on the
basis of its homology with the other enzymes but its substrate specificity is
yet to be elucidated (Basset et al., 1990). The other three known classes of
proteinases (serine, aspartyl and cysteinyl) have also been implicated in
the process of matrix proteolysis. Of most interest is the serine protease,
urokinase-type plasminogen activator. The overexpression of this
enzyme has been related to enhanced invasion and metastasis (Dano et
ah, 1985).
The expression of these proteases is not limited to invasive tumours as
proteolysis also occurs in normal tissues, during tissue remodelling and
in other situations such as bacterial infections. The expression of the
enzymes is highly regulated and even during the process of tumour
invasion the degradation of the matrix occurs in a controlled fashion as
matrix components are required for the next stage of the process, namely
cell migration. The difference between normal and tumour cells is that,
in malignancy the process of membrane degradation is occurring at a time
and place which would be inappropriate for normal cells. Tumour cells
are also able to produce some of these enzymes themselves (Gottesman,
1990), or induce other cells to secrete them. The enzymes are secreted in a
highly localised manner until the active enzyme outbalances the natural
tissue inhibitors of metalloproteinases (TTMPS) (Carmichael et ah, 1986).
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1.2.3 Cell migration
The third step in the invasion of the interstitial stroma involves the
locomotion of the tumour cells through the basement membrane. The
importance of tumour cell motility in invasion and metastasis was first
demonstrated by Corman in 1953. Cell migration again is a highly
coordinated process which can occur in certain normal situations
(Lauffenburger and Horwitz, 1996). The process begins with the
morphological polarisation of the cell followed by membrane extension at
the leading edge to form pseudopodia. The extended part of the cell must
then form attachments to the matrix and produce a contractile force to
move the cell forward. This contractile force appears to be generated by
active myosin based motors. For forward movement the attachment of
the rear of the cell to the matrix must be released and the receptors
binding the matrix are either lost or recycled.
Migration of tumour cells can be promoted by a number of factors
including matrix components (McCarthy and Furcht, 1984), growth factors
(Stracke et al., 1988) and scatter factors (Weidner et al., 1990). These can
stimulate motility either randomly (chemokinesis); in a directional
fashion whereby cells move in response to a gradient of factor
concentration (chemotaxis); or in a directional manner towards substrate
bound ECM proteins (haptotaxis). Tumour cells themselves can also
produce autocrine motility factors (Liotta et al., 1986).
1.2.4 Integrins
The processes of cell attachment and migration involve receptors on the
cell surface. The integrins are a large family of cell surface adhesion
receptors. The original classification of integrins recognised 11 different
human integrins (Flynes, 1987) but there are now 21 different identified
integrins (Yokosaki and Sheppard, 1995).
Structurally all integrins consist of two non-covalently linked subunits.
The a subunits range from 120 to 180 kDa and are linked to a 15 subunit of
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molecular weight 90 to 110 kDa. Both subunits are type I transmembrane
glycoproteins, composed of a large extracellular domain, a hydrophobic
membrane spanning region and a short cytoplasmic domain. The
heterodimers are formed by association of the extracellular domains. The
pivotal roles of integrins are to mediate cell-cell and cell-matrix
interactions and both subunits contain ligand binding sites in their
extracellular domains. The a subunit also contains a binding site for
metal cations. Integrins recognise active site peptides on the ECM
proteins, the best characterised of which is the tripeptide Arg-Gly-Asp
(RGD). The RGD site in fibronectin and tenascin has been analysed and
shown to exist in a flexible loop structure (Main et ah, 1992; Leahy et ah,
1992) The two ligand binding sites on the integrin subunits are closely
associated, therefore the substrate specificity of the integrin is determined
by both the a and fi subunits. Integrins can be monospecific (e.g. a6fil,
which recognises only laminin), or polyspecific (e.g. a3fil, which can bind
fibronectin, collagen laminin and epilgrin); this results in considerable
redundancy in ligand recognition (Hynes, 1992). Table 1.3 shows the
specificity of integrins for selected extracellular matrix proteins.
The specificity of integrins is generally established using purified
subunits, but it can vary depending upon the cell type on which they are
expressed (Kirchofer et ah, 1990). It has also been observed that the
specificity and affinity of integrins on a given cell type is not constant.
Masumoto and Hemler (1993) demonstrated that cells can activate or
deactivate their integrins. Pullman and Bodmer (1992) identified a
cytoplasmic protein which increased the levels of a2Bl-mediated
adhesion to collagen. Integrin function can therefore be regulated from
inside the cell (inside to out signalling) or by binding of external factors
such as matrix proteins (outside to in signalling). There is increasing
evidence that integrins not only act as molecular anchors, but they are
also capable of transducing signals from a cell's environment via the
cytoplasmic domains of the a subunits, which are linked to the
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cytoskeleton. A direct link has been demonstrated between integrins and
tyrosine phosphorylation of the phosphoprotein focal adhesion kinase
(Humphries et al., 1993).
Table 1.3 Specificity of integrins for selected ECM proteins
















It has been known for many years that extracellular matrix (ECM)
molecules play vital roles in organ morphogenesis (Grobstein, 1954).
Many ECM components have been identified, including proteoglycans,
collagens and other glycoproteins. Study of these proteins has shown that
they are not merely structural proteins but they can also bind to cellular
receptors, such as integrins, and affect cell function (McDonald, 1989).
Many ECM molecules are ubiquitous, but the large ECM glycoprotein
tenascin (TN) has a limited distribution and is often only seen in the
mesenchymal ECM at times of important tissue interactions; during
embryogenesis, when tissues are reorganising or regenerating (as in
healing wounds) and also in tumours.
1.3.1 Discovery and nomenclature of tenascin
In hindsight it can be seen that the first reference to TN was actually made
by Yamada et al. in 1975; this group purified cell surface fibronectin and
assigned it the property of haemagglutination. It was noted in 1978 by
Alexander et al. that the fibronectin preparation contained disulphide-
bound oligomers, and in 1984 Erickson and Inglesias used rotary
shadowing electron microscopy to examine these oligomers and found
that they had a distinctive structure of 6 long flexible arms and that the
structure of these arms was different to that of fibronectin. Erickson and
Inglesias concluded this molecule was a new protein and called it
hexabrachion.
At the same time as Erickson and Inglesias were carrying out work on the
fibronectin preparations, Chiquet and Fambrough described a new protein
which they had discovered in connective tissue. This protein too was a
hexameric glycoprotein and they termed it myotendinous antigen
(Chiquet and Fambrough, 1984). Another group was independently
looking for proteins associated with tumours and produced an antibody
to an ECM protein which was prominent in the stroma and vasculature
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and appeared to be absent in normal tissues. They named their protein
GMEM (glioma mesenchymal extracellular matrix) and demonstrated
that it was a disulphide bound oligomer (Bourdon et al., 1985). Two
neurobiology groups also described similar proteins which they named J1
(Kruse et al., 1985) and cytotactin (Grumet et al, 1985).
It eventually became apparent that these diverse studies had identified
the same protein as the homology became obvious. The different areas of
discovery painted a picture of a protein with a very interesting
distribution.
In 1986 Chiquet-Ehrismann et al. demonstrated a link between the novel
ECM protein and tumours. In their paper they also proposed the name
tenascin for this protein. The name is derived from the combination of
the latin verb "tenere" (to hold) and "nasci" (to be born) reflecting partly
its discovery by Chiquet and Fambrough in tendons and also its
embryogenic expression. The name tenascin is now universally accepted.
1.3.2 Structure of tenascin
(i) Hexamer structure
Probably the most distinctive structural feature of TN is its hexabrachion
structure, which can be clearly seen in the rotary shadowed electron
micrographs (Erickson and Lightner, 1988). An illustration of this
hexameric structure can be seen in figure 1.2.
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Figure 1.2
The structure of the TN hexamer
The hexabrachion can be seen to have five distinct features: (a) a terminal
knob, (b) a thick distal segment, (c) a thinner inner segment (d) a "T"-
junction where three arms are connected by formation of a triple coiled
coil of the 3 arms and finally (e) a central globular particle which connects
the 2 trimers by a disulphide bridge to form the hexabrachion structure.
The hexamers are in fact assembled by a novel co-translational process
which is facilitated by the length of the subunits (Redick et ah, 1995).
This hexabrachion is a very large protein whose size is around 2000 kDa.
The protein can be purified from conditioned media using immuno-
affinity chromatography (Chiquet-Ehrismann et ah, 1986) or by standard
biochemical protein purification methods the most important stage of
which involves separation of TN according to its large size.
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(ii) Monomer structure
The TN molecule is a homohexamer and each monomer is built up of
characteristic structural domains, as shown below in figure 1.3.
Figure 1.3
The structure of the TN monomer
|2|3|4|5|A1|A^A3|A4|BMC|D|6F|8Kc)
The TN monomer consists of 5 distinct domains some of which show
homologies to other proteins (Jones et al., 1989). Firstly, an N terminal
domain ( ), which can crosslink the monomers by disulphide bonds. This
domain is followed by heptad repeats which participate in the formation
of the trimer structure. The flexible arms of the hexabrachion molecule
consist of 14 y epidermal growth factor (EGF) like repeats (♦), up to 16
fibronectin type III repeats () and finally a COOH-terminal globe which
is homologous to the globular domain of the £ and y chains of human
fibrinogen.
TN is encoded by a single gene, which has been cloned and sequenced
(Gulcher et al., 1991; Nies et al., 1991) and its expression is regulated by a
single promoter which has been shown to contain a number of response
elements (Jones et al., 1990) including sites for homeobox genes and their
encoded proteins (Jones et al., 1992). It has also been shown that the first
untranslated exon of the gene plays a role in the regulation of TN gene
expression (Gherzi et al., 1995).
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(iii) Alternative splicing
Many eukaryotic genes contain extra sequences which are not present in
their corresponding mRNA; these non-coding sequences are called
introns and the coding sequences are called exons. The primary RNA
transcript of these genes contains the intron sequences which are then
spliced out in a precise multistep process to produce the mRNA which
leaves the nucleus. If every exon in the gene is present in the processed
mRNA then this is known as constitutive splicing and only one protein
is produced from the gene. If individual exons are excluded from some
transcripts and included in others this is known as alternative splicing.
Alternative splicing provides a means of forming a set of proteins that are
variations on a basic motif.
The TN primary mRNA transcript undergoes alternative splicing in its
region of FN type in repeats as illustrated in figure 1.4.
Figure. 1.4 Alternative splice forms of the FN type III repeats of TN.
fllii
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This figure (adapted from Chiquet-Ehrismann, 1993) illustrates the FN
type III repeats of the TN monomer. The shaded boxes represent the
repeats which can undergo alternative splicing. The lines beneath the
diagram indicate possible splice variants, which have been previously
reported in the literature.
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Gulcher et al. (1989) first demonstrated that the human TN gene
underwent splicing and indicated that some forms contained 7 extra FN
type in repeats. Siri et al. (1991) detected 4 of the above variants using
reverse transcription-polymerase chain reactions. That the additional
AD1 repeat existed in some TN variants was discovered by Sriramarao
and Bourdon in 1993.
Which of these RNA splice variants go on to be translated into proteins is
unclear. To date, most groups have reported 2 predominant forms of TN;
large (approximately 300 kDa) and small (approximately 200 kDa).
However there is some evidence that tumour cells may be able to produce
intermediate size forms of the protein. Larger isoforms of TN are more
frequently associated with proliferating tissues.
(iv) The TN family
Two new proteins have been discovered that are related to TN, consisting
of similar domains and potentially having similar functions. A new
nomenclature has been proposed by Erickson (1993) to distinguish
between the members of this family of TNs. The original TN has been
designated TN-C, the C stands for cytotactin, which was the name
associated with the first published sequence. The two new family
members are named TN-R and TN-X. TN-R was discovered as restrictin
in the chicken nervous system (Rathjen et al., 1991) and in the rat the
same protein was identified and named Jl-160/180 (Pesheva et al., 1989).
Both proteins have subsequently been cloned (Norenberg et al., 1992; Fuss
et al., 1993). The TN-X gene was discovered in the human major
histocompatibility complex class III locus and has since been sequenced by
Bristow et al. (1993).
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The basic structure of these 3 main family members is shown in figure 1.5
Figure 1.5 The TN family
TN-R
I I I I I 11 I hQ
TN-C
I I I I II I I II I I I I I K3
TN-X
I I I I I I
Each form of TN contains the C-terminal fibrinogen like domain and
various numbers of FN type in repeats ranging from 9 possible repeats in
TN-R to 29 repeats in TN-X. The final FN type in domain is conserved in
all 3 proteins.
It is very likely that more members of the family will be identified.
Chiquet-Ehrismann et al. (1994) have discovered in chicken the partial
DNA sequence of a new member which they have tentatively termed
TN-Y and believe they have further evidence for the existence of other
TN-like genes. Research has also identified 2 proteins in Drosophila,
which may be invertebrate TN.
1.3.3 Distribution
The main interest in TN sprang from observation of its spatial and
temporally restricted distribution pattern. During normal embryogenesis
TN is prominent in the developing nervous system, in matrix lining the
pathway of migrating cells, in mesenchyme at sites of epithelial-
mesenchymal interaction and in developing connective tissue. The
original discoveries of TN in developing organs and in tumours lead to
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the belief that TN may be a true oncofoetal protein. This belief appeared
to have been substantiated by Mackie et al., (1987), who showed that TN
was only present in the stroma of malignant breast tissue and was not
seen in benign or normal samples. However it has since become apparent
that the antibody used to detect TN recognised part of the alternatively
spliced FN type HI repeats and was therefore detecting only the largest
isoforms of the molecule (Borsi et al., 1992).
Since this discovery TN has been detected in some normal tissues but at
much lower levels than in foetal counterparts. In cases of disease or
injury, expression can, however, be greatly increased (see references
below).
(i) Normal tissues
TN is most strongly expressed in regenerative organs such as the gut
(Aufderheide and Ekblom,1988) and the skin (Lightner et al., 1989) in
which the epithelium is being constantly renewed. Lower levels of
expression have been detected in other adult organs and tissues. Borsi et
al. (1993) detected TN mRNA in a wide range of tissues and organs
including heart, brain, lung, liver and kidney. Ventimiglia et al. (1992)
also demonstrated TN protein in normal adult brain and kidney. TN is
also found in the smooth muscle wall of blood vessels (Mackie et al.,
1992).
Interestingly, a marked increase in TN expression can be seen when
cellular proliferation and reorganisation are occurring. The most obvious
example of this phenomenon is in healing wounds in which the levels of
TN are markedly increased at the dermal-epidermal junction beneath the
regenerating epidermis (Mackie et al., 1988). TN expression is also
increased in hyperproliferative skin diseases such as psoriasis (Schalkwijk
et al., 1991).
In the normal adult breast, which was previously thought not to express
TN, it has been shown that TN can be detected during gestation and
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lactation (Howeedy et al., 1990). Levels of TN expression in normal breast
vary according to the stage of the menstrual cycle, with the highest level
of TN expression at day 22 of the cycle which corresponds to the peak in
mitosis (Ferguson et al., 1990).
Tamura et al. (1993) have demonstrated the presence of TN in normal
ovary by immunohistochemistry. The expression of the protein varied
widely according to the stage of the menstrual cycle. Little staining was
observed in preovulatory follicles, and only low levels of expression were
seen in functioning corpora lutea. Ovaries undergoing reorganisation,
caused by the involution of the corpora lutea, were associated with much
stronger TN staining.
(ii) Tumours
Since the original findings of increased expression of TN in gliomas
(Bourdon et al., 1985) and breast tumours (Mackie et al,. 1987),
overexpression of TN has been reported in many other solid tumours by
immunohistochemistry. A summary of the tumours studied is shown in
table 1.4.
All the cases investigated showed that there was an increased incidence of
intense and diffuse staining, in the ECM of the stromal mesenchyme, in
malignant tumours, when compared to normal or benign tissue. For
example Ibrahim et al. (1993) demonstrated, in human prostate tissue,
that while most samples studied were positive for TN staining (80% of
benign and 96% of malignant), the benign tissue generally did not show




Tumours shown to overexpress TN
Tumour type Reference
glioma Bourdon et al. 1983
basal cell carcinoma Stamp et al. 1989
endometrium Vollmer et al. 1990
melanoma Herlyn et al. 1991
breast Koukoulis et al. 1991
lung Oyama et al. 1991
colon Reidl et al. 1992
liver Yamada et al. 1992
prostate Ibrahim et al. 1993
salivary gland Shrestha et al. 1994
astrocytoma Zagzag et al. 1995
However the expression of TN has not been examined in ovarian
tumours.
1.3.4 The nature of the cells producing tenascin.
It has generally been assumed that the cellular source of TN in tumours is
the stromal cells surrounding the epithelium. This is mainly because of
observations of immunohistochemical staining patterns and
experiments with epithelial cells in culture (Sakai et al., 1993). It has since
been shown that epithelial cells are capable of producing TN in vivo.
Lightner et al. (1994) demonstrated by in situ hybridisation that epithelial
cells are an important source of TN in both normal and malignant breast
tissue. Other studies have shown that many epithelial cells are capable of
secreting TN in vitro (Kawakatsu et ah, 1992).
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Whatever the cellular source of TN it is clear that increased levels are
seen where there are epithelial-mesenchymal interactions. Several
findings have suggested that TN synthesis is induced in the stroma as a
result of interactions with neoplastic epithelium. Chiquet-Ehrismann et
al. (1989) demonstrated that conditioned media from the MCF-7 breast
carcinoma cell line induced TN synthesis in fibroblasts. More recently it
has been shown that the converse can also occur and fibroblasts can
induce TN synthesis in epithelial cells (Hiraiwa et al., 1993: Sakai et al.,
1995).
1.3.5 Regulation of tenascin synthesis
(i) Growth factors and cytokines
It is clear, from TN's temporally and spatially restricted distribution
pattern, that the expression of this protein is tightly regulated. Epithelial-
mesenchymal interactions have been shown to induce TN synthesis, and
this induction does not rely solely on direct contact between the cells but
may be mediated by soluble factors (Hiraiwa et al., 1993).
Serum is a potent inducer of TN and fractionation by heparin affinity
chromatography has provided several active fractions, indicating that
there are several factors capable of inducing TN in serum (Vrucinic-Filipi
and Chiquet-Ehrismann, 1993).
Many growth factors and cytokines have been tested and shown to induce
TN synthesis. These include: TGF-fii (Pearson et al., 1988), EGF (Sakai et
al., 1995), FGF (Tucker et al., 1994), IL-1 and IL-4 and TNF-a (Rettig et al.,
1994), activin (Umbhauer et al., 1992), PDGF (Sharifi et al., 1992) and
angiotensin II (Mackie et al., 1992). The effects of many of these factors are
cell specific, showing the dependence of a response on the presence of
receptors and requirement for second messenger pathways.
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(ii) Hormones
There is some evidence that TN synthesis may be regulated by hormones.
Vollmer et al. (1994) showed that hormones such as progesterone could
affect TN synthesis indirectly, by altering the proliferative activity and
degree of differentiation of the epithelium. They found that a low degree
of differentiation induced TN expression.
Glucocorticoid hormones have been shown to inhibit TN expression in
bone marrow and fibroblast cells (Ekblom et al., 1993).
(iii) Mechanical stress
Chiquet-Ehrismann et al. (1994) showed that mechanical stress, generated
by culturing cells in restrained collagen gels, could induce TN secretion in
fibroblasts.
1.3.6 The search for a function
The association of TN expression with epithelial proliferation and
morphogenesis, as well as its overexpression in tumours and healing
wounds has lead to speculation that TN plays a significant role in
regulating cell function. In vitro, studies have shown TN is capable of
producing varying effects on the behaviour of cell lines.
(i) Adhesion and spreading
Because of TN's modular structure and homology to fibronectin, many
studies of the protein have investigated its role in cell adhesion. One of
the most widely reported properties of TN is its "anti-adhesive" activity.
Chiquet-Ehrismann et al. (1989) and Kawakatsu et al. (1992) found that
MCF-7 breast carcinoma cells adhere poorly to TN and Herlyn et al. (1991)
showed that TN is also a poor substrate for melanoma cell adhesion.
Chiquet-Ehrismann et al. (1988) showed that TN could interfere with the
adhesive action of FN, inhibiting integrin mediated attachment of cells to
this protein. Both Chiquet-Ehrismann et al. (1991) and Chung et al. (1995)
have demonstrated that TN can physically bind to FN. Lightner et al.
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(1990) showed TN can possibly interfere with cell binding to ECM
proteins sterically blocking cell access to the matrix.
However, TN has also been shown to have adhesive properties. Spring et
al. (1989) used recombinant fragments to elucidate how TN could be both
adhesive and anti-adhesive. They observed that there was a strong cell
binding site at the tip of the TN arm while, in contrast, the fragment
containing the EGF-like repeats showed an anti-adhesive effect.
Many studies have also demonstrated that TN can promote cell
attachment but inhibit cell spreading (Chiquet-Ehrismann et al., 1988;
Spring et al., 1989); this may indicate that the signals for these two
processes exist on different parts of the molecule and may be mediated by
different receptors.
The contrasting reports in the literature indicate that TN's effects on
adhesion and spreading are cell type specific, but it should also be noted
that the source of TN used in these different studies has not been
uniform and it is very likely that different isoforms of TN will have
different properties. In support of this Murphy-Ullrich et al. in 1991
showed that only the larger form of TN-C resulted in loss of focal
adhesion of epithelial cells.
(ii) Migration
In developing embryos TN is located along the pathway of migrating cells
particularly in the developing nervous system (Mackie et al., 1988). Again
experiments examining the effects of TN on migration in vitro have
produced apparently contradictory results. Giese et al. (1995) showed that
TN is a permissive substance for glioma cell migration; Deryugina and
Bourdon (1996) demonstrated the same effect and also demonstrated that
TN modulated cell migration on FN. Hoffman et al. (1994) found that TN
inhibited the migration of monocytes through a matrigel coated porous
membrane. Thus it appears that the effects of TN on cell migration may
be cell specific.
31
(iii) Other effects of TN
TN expression is enhanced in regions of increased proliferation, and the
TN molecule contains regions homologous to the growth factor EGF;
these observations suggest that TN may be capable of acting as a growth
factor. TN has been shown to be growth stimulatory to rat tumour cells
(Chiquet-Ehrismann et ah, 1986). End et ah (1993) demonstrated TN could
stimulate the growth of quiescent Swiss 3T3 fibroblasts; they also showed
that the TN molecule was internalised in these cells. In contrast Crossin
(1991) showed that TN inhibited DNA synthesis in rapidly proliferating
3T3 cells.
Expression of TN may also correlate with angiogenesis (Zagzag et ah,
1995). As angiogenesis is a process which involves cell movement and
reorganisation, and TN is expressed in the vascular smooth muscle wall,
it seems likely that TN's adhesive and migratory properties may be
involved in this process. Hahn et al. (1995) showed that TN provided a
substratum for directed endothelial and smooth muscle cell migration.
Additionally Canfield and Schor (1995) described how TN can promote
endothelial cell sprouting; this is a transition from a resting phenotype to
an angiogenic phenotype.
TN has been shown to be capable of inducing genes such as c-fos and
several proteinases including 92 kDa gelatinase, stromelysin and
collagenase (Tremble et ah, 1994). Interestingly, TN can be digested by
many proteinases including stromelysin (Imai et al., 1994). These effects
were only seen in the context of a matrix of mixed substrates and were not
mediated by soluble ECM proteins. Chiquet-Ehrismann (1991) states that
ECM proteins which disrupt cell adhesion or alter cell morphology could
greatly effect cellular function by causing the release of cytoskeleton
associated factors of second messenger pathways. Different cell types
would, therefore, produce different responses to the ECM depending on
the receptors, cytoskeleton components and second messenger systems
present. TN may also be involved directly in intracellular signalling
through its cell surface receptors, described in section (iv) below.
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Additional functions of TN have been shown to include alteration of
cellular pH (Krushel et ah, 1994), immunosuppressive activity (Ruegg et
ah, 1989) and differentiation of mammary cells (Chammas et ah, 1994).
Vollmer (1994) speculates that TN may be expressed in reorganising
tissues as a "survival factor7' suppressing apoptosis.
(iv) TN receptors
TN was shown to mediate cell attachment by interacting, through an
arginine-glycine-aspartic acid (RGD) tripeptide, with a cell surface receptor
(Bourdon and Ruoslahti, 1989). This indicated that TN interacted with
integrin type receptors as described in section 1.2.4. TN has since been
shown to interact with several integrins, including a2fil and aVfi3
(Sriramarao et ah, 1993), aVfi6 (Prieto et ah, 1993), a8fil (Schnapp et ah,
1995) and a9fil(Yokosaki et ah, 1994). These integrins may be present on
different cell types and have different functions. The relevance of
integrins to TN is reviewed by Yokosaki and Sheppard (1995).
Several other candidates for TN receptors have also been proposed
including Fll/ contactin, which is a member of the Ig super-family of cell
surface/adhesion molecules, and is abundant on neurons (Vaughan et ah,
1994). Annexin II was identified as a high affinity receptor for TN by
Chung and Erickson in 1994. It appears to be a receptor for the
alternatively spliced FN type III domains and may mediate cellular
responses to soluble TN. A further candidate as a TN receptor is the
receptor tyrosine phosphatase fi, the external domain of which is the TN
binding proteoglycan called phosphacan (Barnea et ah, 1994). It has been
proposed that the adhesive functions of TN act through the integrins and
the anti-adhesive functions are through the proteoglycans/annexin II.
The presence of many types of receptor which can bind different variants
of TN may partly explain the contrary and cell specific actions of TN.
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(v) The function of TN in vivo
In order to provide definitive answers to the questions about the
fundamental functions of TN, Saga et al. (1992) genetically engineered
mice by homologous recombination to knock out the TN gene. Their
initial finding was that these TN-null mice developed normally.
Superficially this may be surprising if TN has a pivotal role in tissue
reorganisation. However, it is possible that other members of the TN
family may be capable of substituting the function of TN-C. Subsequently
further investigations have shown that "knockout" mice display
developmental differences (Steindler et al. 1995) culminating in abnormal
locomotion (Fukamauchi et al., 1996).
While TN clearly plays a role in embryogenesis, its role in tumour
genesis and behaviour is still under investigation. The adhesive and
anti-adhesive properties of the molecule have suggested that TN may
play a role in tumour invasion and metastasis. The relationship with
angiogenesis (Zagzag et al., 1995) and the induction of proteinases
(Tremble et al., 1994), are also compatible with an involvement in the
metastatic process, as was reviewed in section 1.2.
1.3.7 Potential roles of tenascin in tumour detection and therapy
(i) TN expression and prognosis
The relevance of TN as a prognostic factor has been investigated in a
number of solid tumour types and as with many other aspects of TN
research, these studies have produced contradictory results. In studies of
TN expression in colon cancer Sugawara et al. (1993) found that colonic
cancer cells were not as invasive when surrounded by TN. The presence
of TN in the sera of patients with colon cancer was also investigated; TN
concentrations were found to be significantly higher in the sera of cancer
patients when compared to healthy individuals (Riedl et al., 1995).
However, Schenk et al. (1995) demonstrated that elevated TN levels were
present in sera of patients with increased levels of acute phase protein
due to infection or inflammation. In breast cancer, Moch et al. (1993)
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found no correlation of stromal TN expression with established
prognostic factors such as nodal metastases and invasion of blood vessels;
they did, however, demonstrate a link between local inflammatory
response and degree of TN expression.
The link between TN and local inflammatory reactions is logical as it has
been demonstrated that TN synthesis may be stimulated by cytokines,
such as IL-1 and IL-4 (Rettig et al., 199). This is also consistent with
theories put forward by Dvorak (1986) that tumours are wounds that do
not heal. As Dvorak describes, most solid tumours require stroma if they
are to grow beyond a size of 1-2 mm; this stroma develops in much the
same way in tumours and healing wounds. The initial stages of stroma
development involve the deposition of a fibrin-fibronectin gel; this gel is
then infiltrated by inflammatory cells (primary lymphocytes and
macrophages) and fibroblasts. The fibrin-fibronectin gel matrix is
degraded and mature matrix proteins are subsequently deposited; as
described previously there is overexpression of TN in matrices in both
tumours and healing wounds. Further studies in breast cancer have
demonstrated that there is a link between the cellular source of TN and
prognosis (Ishihara et ah, 1995). Their data indicated that patients whose
cancer cells produced TN had a poor prognosis with increased likelihood
of lymph node metastasis.
(ii) TN as a target for immunotherapy
It has been demonstrated that the larger form of TN protein is more
frequently expressed in neoplastic tissue than in normal tissue (Borsi et
ah, 1992). Antibodies are available which recognise epitopes within the
alternative spliced region of TN (Balza et ah, 1993), thus making them
specific for the larger isoform of the protein. This overexpression of a
specific isoform of TN in tumours is already being exploited for both the
visualisation and potential therapy of gliomas. Gliomas were one of the
first sites of discovery of TN (Bourdon et ah, 1985) and the expression of
TN is well characterised. Gliomas were also one of the first systems to be
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tested with anti-TN antibodies as they are suitable for intralesional
therapy, due to their lack of metastasis and good compartmentalisation
(Riva et al., 1992).
The monoclonal antibody BC-2 is currently being used to visualise
gliomas using avidin-biotin labelling in a three step process (Leprini et al.,
1994). The BC-2 antibody is also being used in immunoradiotherapy of
gliomas, as a means of delivering radioisotopes to gliomas (Riva et al.,
1994). Davico-Bonino et al. (1995) have also developed a bispecific
monoclonal antibody, which utilises TN as the tumour targeting
molecule and also recognises the CD3 activation site of lymphocytes.
1.4 Scopes and objectives of this study.
The previous section details the expression and possible functions of TN
in a number of solid tumours. Tamura et al. (1993) had demonstrated TN
was present in samples of normal ovary, but it was unknown whether
TN is expressed in ovarian tumours.
This thesis examines the expression and potential roles of TN in ovarian
cancer. There are three main areas of study, the results of which are
presented as separate chapters:
(1) Expression of TN in ovarian tumours
A series of ovarian tumours (including malignant, borderline and benign
forms) were examined and compared for the expression of TN protein
and RNA. The relationship between TN expression and factors such as
hormone receptors and growth factors were also investigated to explore
potential regulators of TN expression in vivo.
(2) Expression of TN by ovarian cell lines
Established ovarian carcinoma cell lines were used alongside cultures of
ovarian fibroblasts developed from the ascites of patients with ovarian
cancer. The use of these cell lines enabled examination of the cell types
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producing TN and a study of its regulation. It has been speculated that the
synthesis of TN may be under paracrine control and a co-culture model of
the fibroblast and epithelial cells was used to establish whether a
paracrine loop may exist in ovarian tumours. Several growth factors and
hormones were investigated as potential modulating factors.
(3) Functions of TN
TN has been implicated in processes central to the development and
spread of cancer, effects having been shown on cell adhesion, migration
and proliferation. Cell lines were again utilised to examine the
interactions of ovarian carcinoma cells with TN. The adhesive aspects of
TN function involve cellular receptors; several integrins have been
shown to recognise and bind TN and the expression of integrins on the
cell lines was investigated.
The results from all three areas of study are summarised in a final
section, which relates the data from the ovarian cell lines to the patterns
of TN expression observed in the ovarian tumours. The role of TN in







Listed by technique. All chemicals from Sigma unless otherwise stated.
2.1.1 Ovarian tumours
Tumour material was collected from patients presenting with ovarian
tumours at the time of their initial surgery. Pathological data detailing
histology, stage and grade was available for all samples. The samples
were stored in liquid nitrogen.
2.1.2 Tissue culture
(i) General culture materials
DMEM
DMSO
Fetal calf serum (FCS)







- Gibco Life Technologies
- BDH AnalaR
- Advanced Protein Products
- Ovoid
- Gibco Life Technologies
- Falcon
- Boehringer-Mannheim
- Serono Laboratories (UK) Ltd.
- Serono Laboratories (UK) Ltd.
-R&D Systems
Human recombinant EGF, TGF-a, IGF-I, IGF-II and ylFN were
reconstituted in sterile PBS and stored in appropriate aliquots at -40°C.
Human recombinant TGF-fii was reconstituted in 4 mM HC1 containing
BSA (1 mg/ml) and again stored at -40°C. Progesterone and fi-oestradiol
were dissolved in ethanol to give stock solutions of 10"2 M and stored in
glass bijou bottles at 4°C in the dark. Stock solutions of the
gonadotrophins HCG and FSH, which had been extracted from human
urine, were made up in sterile NaCl diluent solution as provided with
each ampoule of hormone (5000 IU/ml and 75 IU/ml respectively). HCG
was used as a substitute for LH, due to its similarity to this hormone and
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increased availability
(ii) Epithelial Cell Lines
The PEOl and PE04 cell lines were derived from the ascites of the same
patient with a poorly differentiated serous adenocarcinoma (Langdon et
al, 1988). The PE01CDDP cell line was obtained by continuous exposure of
the PEOl cell line to increasing concentrations of cisplatin.
59M, a human ovarian tumour epithelial cell line and SKOV-3, a human
ovarian adenocarcinoma cell line, were obtained from the European
Collection of Animal Cell Cultures (ECACC).
The breast carcinoma cell lines MDA-MB-231, T47D and ZR-75-1 were also
obtained from the ECACC.
(iii) Fibroblast Cell Lines
The fibroblast cell lines were cultured from the ascites of patients with
primary ovarian cancer.
2.1.3 Immunohistochemistry
All antibodies were from DAKO Ltd.
Avidin biotin complex - DAKO Ltd
DPX synthetic mounting media - Fisons
Xylene - Fisons
2.1.4 Reverse transcription pi
(i) RNA preparation
Tri reagent LS (for cell lines)





irase chain reaction (RT-PCR)
- Molecular Research Centre Inc.







Reaction mixture components all from Promega
123 bp ladder - Gibco BRL
Primers - ICRF Oligonucleotide Synthesis
Laboratory
Superscript II reverse transcriptase - Gibco BRL
Taq polymerase - ICRF
Thermal cycler - Techne
(iii) Probing
y32p ATP




All antibodies from DAKO Ltd.
Human tenascin
Immulon 4, 96 well trays
2.1.6 Functional Assays
Flexible 96 well trays
Hanks Balanced Salt Solution
48 well trays
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(i) Routine Culture of Cell Lines
All cell lines were routinely cultured in Dulbeccos modified Eagle
Medium (DMEM) at 37°C in an atmosphere of 5% CO2 in a humidified
incubator. The media was supplemented with L-glutamine (2 mM),
penicillin (100 IU/ml), streptomycin (100 pg/ml) and 10% foetal calf
serum (FCS) which had been heat-inactivated by incubation at 56°C for 20
min.
(ii) Establishment of fibroblast cell lines
Vials of ascitic fluid were removed from liquid nitrogen and allowed to
defrost. The tube contents were resuspended in 10 ml of prewarmed
DMEM (+10% FCS), centrifuged at 2000 rpm for 3 min and washed twice
in 5 ml of the same media. After the final wash, the cell pellet was
resuspended in a further 5 ml of media. An aliquot was retained for the
preparation of multispot slides, and the remainder was transferred to a 25
ml tissue culture flask with a further 5 ml of media. The fibroblast cells
adhered rapidly to the plastic surface of the flask and after 2-4 h the media
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could be taken off, leaving behind a pure population of fibroblasts which
were refed with fresh media. After the cells had been growing for 2-4 days
any remaining contaminating non-fibroblast cells were removed by
differential trypsinisation, the fibroblasts detaching more rapidly than the
other cell types. Once the fibroblasts were well established (after 1-2
passages) an aliquot of cells was again taken for preparation of multispot
slides. To prepare multispot slides the cells were washed in serum free
media, counted on a haemocytometer and resuspended at a density of 5 x
105 cells/ml. An aliquot of this suspension (20(0.1) was added to each well
of a multispot slide and allowed to air-dry overnight before being fixed in
acetone: methanol (50%: 50% v:v) for 10 min at room temperature. These
slides were stored at -20°C until use.
(iii) Cell harvesting
Routinely, cells were grown to confluence in 75 or 175 cm2 flasks and fed
with fresh media every 3-4 days, before being harvested, usually once a
week. The confluent flasks were washed in phosphate buffered saline
(PBS), pH 7.3, to remove traces of FCS. Cells were detached from the
plastic by incubation with a 1:1 solution of trypsin (0.25% [w/v] in Gibco
solution A) and versene ( 1 mM EDTA in PBS, 0.5% [v/v] phenol red), for
5-20 min at 37°C. The trypsin was inactivated by the addition of DMEM
(+ 10% FCS). If the cells formed clumps during harvesting, single cell
suspensions were produced by syringing the cells through a 21.5 gauge
needle.
(iv) Cryopreservation and recovery of cells from liquid nitrogen
Cells to be stored were harvested as described above and the cell
suspension was centrifuged to give a cell pellet. This pellet was
resuspended in ice cold freezing mixture (10% [v/v] dimethyl sulphoxide
[DMSO] in newborn calf serum). Aliquots were transferred to cryotubes
and stored in liquid nitrogen.
To recover cells the samples were thawed and washed with DMEM (+
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10% FCS) then transferred to flasks as described in section 2.2.1 (ii).
Epithelial cells were allowed to attach overnight at 37°C before the media
was changed to remove dead cells and traces of DMSO.
(v) Cell counting
In order to estimate cell numbers for setting up experiments, cells were
counted using a haemocytometer; however for counting of cells in
multiple well trays a ZF Coulter Counter was used. The medium was
removed from the wells; if FCS had been present cells were washed in
PBS, pH 7.3. Cells were detached from the wells by incubation with 250 pi
of 1:1 trypsin/versene solution and aliquots (200pl) of the cell
suspensions were added to 9.8 ml of NaCl (0.9%). Each suspension was
counted in duplicate. Cell numbers per well were calculated by
multiplying by the dilution factor (x25).
2.2.2 Immunohistochemistry.
(i) Tumour sections
Frozen sections of the tumours (cut on a cryostat) were incubated with
20% foetal calf serum in tris buffered saline (TBS/FCS) for 10 min at room
temperature. The sections were then incubated with monoclonal mouse
anti-human tenascin antibody, diluted 1:100 in TBS/FCS, for 30 min at
room temperature in a moist chamber. Control sections were treated with
primary antibody absorbed with excess pure TN or with TBS/FCS. After
washing in TBS, sections were covered in rabbit anti-mouse biotinylated
antibody diluted 1:100 in TBS/FCS, followed by avidin-biotin peroxidase
complex made up in TBS; both incubations were for 30 min at room
temperature, in a moist chamber, and were followed by washing in cold
TBS. After the final wash, sections were treated with a 1 mg/ml solution
of 3,3'-diaminobenzidine, containing 5% hydrogen peroxide, for 5 min.
The sections were counterstained lightly with haematoxylin. Finally the
sections were dehydrated, cleared and mounted under coverslips with
DPX synthetic mounting medium. Sections were examined, and
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distribution and intensity of staining assessed, by two independent
readers.
(ii) Multispot slides
The multispot slides were processed in a similar manner to the tumour
sections with identical incubations and washes. The primary antibodies
used were monoclonal mouse anti-human fibroblast (diluted 1:100),




Frozen tumour samples (—100 mg) were dismembranated, using a Mikro-
Dismembrator, to a fine powder which was then added to 2 ml of Tri-
Reagent ™. The extraction of RNA was carried out according to the Tri-
Reagent protocol; chloroform and isopropanol were used to precipitate
the RNA, which was then washed in cold ethanol. The RNA samples
were dried and resuspended in RNase free water. Samples were diluted
(5 |il in 1295 pi) and their absorbance at 260 and 280 nm read in a
spectrophotometer. Yield and purity ratios were calculated. The standard
absorption coefficient for RNA is 40.





The acceptable limits for the purity ratio are between 1.6 and 2.
(ii) Cell Lines
Confluent flasks of cells were used to prepare RNA using Tri-ReagentLS,
in a protocol similar to that for tumours. Additional RNA samples for
ovarian, cervical and breast carcinoma cell lines were donated by
Genevieve Rabiasz.
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(iii) RNA Formaldehyde agarose Gels
The integrity of the RNA was determined by electrophoresis of samples
in denaturing agarose gels. Samples were incubated for 10 min at 65°C
with a denaturing buffer containing formaldehyde and formamide.
Ethidium bromide and loading buffer (EDTA [1 mM], glycerol [50% v:v],
bromophenol blue [0.25% w:v], xylene cyanol [0.25% w:v]) were added and
the samples were then run on a 1.1% agarose, 6.5% formaldehyde gel at
60V for 2h. The RNA was visualised and photographed under UV light.
2.2.4 RT-PCR
(i) Reverse Transcription.
RNA (5|ig) was reverse transcribed using Superscript II reverse
transcriptase in a reaction mixture (total volume 20|il) containing 1.875
mM MgCl2, 10 mM tris, 50 mM KC1, 0.1% Triton X-100, 0.3 mM dNTPs, 20
units RNasin and 120 ng random hexamer to prime the reaction. Prior to
the addition of reverse transcriptase and RNasin, the mixture containing
the RNA was heated to 65°C for 5 min to remove any secondary structure.
After addition of the enzyme, the sample was incubated at 42°C for 1 h.
The reaction was terminated by a 5 min incubation at 95°C.
(ii)Primer design and purification.
All PCR primers were synthesised using cyanoethyl chemistry and were
routinely supplied fully deprotected and dried down. The primers were
purified by precipitating in sodium acetate (60 mM) and MgCl2 (2 mM) in
60% cold ethanol (v/v).
The primers designed to amplify TN cDNA were adapted from Siri et al.
(1991). These primers are located on the periphery of the alternatively
spliced region of TN's fibronectin type III repeats. Primers were also used
to amplify cDNA of the house keeping gene, hypoxanthine-guanine
phosphoribosyltransferase (HPRT). Details of primer sequences and their
products are shown in table 2.1.
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Table 2.1 PCR primer sequences














(iii) Polymerase chain reaction
Reverse transcribed product (equivalent to l|ig of RNA) was added to a
PCR reaction mixture (total volume 20pl) containing 10 pmol of each
primer, 0.3 mM dNTP and 2.5 units of taq polymerase in a reaction buffer
containing (1.875 mM MgCl2, 10 mM Tris, 50 mM KC1 and 0.1% Triton X-
100). The samples were vortex mixed and a drop of light mineral oil was
added in order to prevent evaporation of the sample. PCR was carried
out for 35 cycles of 93°C, 1 min; 53°C, 1 min; 72°C, 1 min. The final cycle
was 72°C for 5 min to ensure complete reaction of final products. The
PCR products were run on a 1.4% agarose gel containing ethidium
bromide for 90 min at 100V. The positions of the bands were noted
under UV light.
2.2.5 Specific Oligonucleotide Hybridisation
(i) DNA Transfer
After the positions of the bands had been noted, gels were destained by
immersing in distilled water for 30 min. DNA was transferred to a nylon
membrane overnight by capillary action using alkaline transfer (0.4 M
NaOH). After the transfer was complete, the membrane was allowed to
air-dry before being sealed in a plastic bag and stored at 4°C until required.
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The gel was restained in ethidium bromide solution for 30 min and the
efficiency of the transfer was checked under UV light.
(ii) Probe Labelling
Oligonucleotides were designed to distinguish the various isoforms of
TN. Details of these oligonucleotides can be seen in table 2.2.
Table 2.2 Probe sequences and specificities
Name Sequence Products
detected




oligonucleotide A4 TTAGCCGTGTCTGAGGTTGG 1921 bp
1651 bp
oligonucleotide B TGATTCCAATAGGTTGCTGG 1921 bp
1651 bp
556 bp
oligonucleotide C GTAACGGTGGTGGATTCTGG 1921 bp
The probes were named according to the FN type in repeat in which they
are located. This table illustrates the splice variants, identified by Siri et at
(1991), with which the oligonucleotides are capable of hybridising.
These oligonucleotides were end-labelled with y32P ATP. Oligonucleotide
(20 ng) was labelled with 1.85 mBq of y32P ATP, in a reaction mix
containing 3 units of T4 polynucleotide kinase, in lx forward exchange
buffer (provided with enzyme). The mixture was vortex mixed and
incubated for 30 min at 37°C.
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(iii) Hybridisation and Washing
Membranes were submerged in saline sodium citrate (SSC) at 6x the
standard concentration (0.15 mM sodium chloride, 15 mM sodium citrate)
and carefully rolled between two pieces of nylon gauze, to exclude air
bubbles. The membranes and gauze were placed in hybridisation oven
tubes and were prehybridised for 30 min at 48°C in hybridisation solution
(SSC at 5x the standard concentration containing 0.1% sodium dodecyl
sulphate SDS, 0.1% sodium pyrophosphate, 0.05% bovine serum
albumin, 0.05% polyvinyl pyrolidine, 0.05% ficol.)
Labelled oligonucleotide was added to 25 ml of hybridisation solution.
The prehybridisation solution was poured off the membranes and the
label was added. Hybridisation was allowed to occur for 4h at 48°C. Filters
were rinsed twice and then washed four times at 48°C for 15 min in SSC
(4x standard concentration), 0.1% SDS, 0.1% sodium pyrophosphate. The
filters were sealed in plastic and autoradiography was carried out at room
temperature. Filters were exposed, to X-ray film, for 30 min to 48 h to
obtain the optimum signal.
(iv) Reprobing
In order to reprobe the same membrane with different probes, the
radiolabeled oligonucleotides were stripped from the membrane by
incubating in 0.4 M NaOH for 30 min at 45°C. The membrane was then
washed twice at room temperature for 10 min in 0.1 x SSC, 0.1% SDS,
0.2 M tris-HCl (pH 7.0). After stripping the membrane was
autoradiographed to check no radiolabel remained.
2.2.6 Measurement of TN Secretion
(i) Production of Conditioned Medium
Cells were plated onto tissue culture flasks or trays at high density in
DMEM (+10% FCS) and left overnight to allow attachment to the plastic.
The serum-containing medium was then removed and the cells were
washed in PBS before the addition of serum-free medium, phenol red-
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free DMEM containing HITS (10 nM hydrocortisone, 5 pg/ml insulin,
10 pg/ml transferrin and 30 nM sodium selenite). After a wash-out
period (~12h) fresh media were added and the cells incubated for 48h.
After this time the conditioned medium (CM) was collected and
centrifuged in polypropylene tubes at 2000 rpm to remove dead cells and
other debris. The cells were then harvested and counted on either a
haemocytometer or the coulter counter as described previously. The
media were immediately analysed for TN by ELISA as described below.
(ii) Enzyme linked immunosorbant assay (ELISA)
96 well plastic plates (Immulon 4) were coated overnight with purified
TN diluted in PBS (200pl) to give a range of 0.5 - 16 ng per well for
generation of a standard curve. Each sample of CM (200pl), was also added
to wells for overnight incubation. CM was assessed neat and diluted 1:2
with PBS. Following the overnight incubation the plates were thoroughly
washed with PBS containing 0.5% tween-20 (PBS-T). The plate was then
incubated for 2h at 37°C with mouse anti-human TN monoclonal
antibody at a 1:160 dilution in PBS-T while replicate wells were left in
PBS-T as a measure of background binding. The plates were then washed
again in PBS-T and incubated with rabbit anti-mouse Ig diluted 1:1000 in
PBS-T for lh at 37°C before a final washing in PBS-T. 50 mg of
orthophenylenediamine (OPD) was dissolved in 100 ml of substrate buffer
(0.71 g anhydrous Na2HPC>4, 0.5 g citric acid, pH 5.0). Immediately prior to
use, 20pl of hydrogen peroxide was added. OPD solution (200 pi) was
added to each well and the plate was incubated for 10 min at room
temperature in the dark. The reaction was terminated by the addition of
50 pi of 0.5 M sulphuric acid and the optical density of each well was
measured on a spectrophotometer at a wavelength of 492 nm.
50
2.2.7 Modulation of TN secretion
(i) Co-culturing experiments
Tissue culture inserts with 8|im diameter pores were used to co-culture
fibroblast and epithelial cells. These inserts keep the cells physically
separate but allow diffusion of potential paracrine factors. The cells to be
co-cultured were harvested by trypsinisation and counted on a
haemocytometer. Fibroblasts (2xl05) were added to the well and a similar
number of PEOl epithelial cells were added to the inserts (in a separate
tray). The cells were allowed to attach for 24h in DMEM (+10% FCS) and
incubated overnight in DMEM (+ HITS). After this time the inserts were
moved to the tray containing the fibroblasts.
Quadruplicate wells were set up with 3 different cell mixtures:
(i) fibroblasts with PEOl cells in the insert, (ii) fibroblasts with empty
inserts and (iii) inserts with PEOl cells in a well containing no fibroblasts.
Fresh serum-free medium was added to the well and the insert (500|il and
300pl respectively). The cells were incubated for 48h at 37°C and counted;
the media were collected and assayed for TN content by ELISA.
(ii) Addition of growth factors
Cells were harvested and plated out in serum-containing medium, in 24
well trays (2.5 xlO5 cells per well). After overnight attachment the cells
were washed, changed to serum-free conditions (DMEM + HITS) and
incubated overnight.
The growth factors, hormones and cytokines whose effects were to be
tested were made up to a single concentration in the serum-free media.
These concentrations had previously been determined to produce a
biological response in ovarian systems.
The factors were added to the cells in a total volume of 500|il of medium.
The cells were incubated for 48h, counted and the medium assayed for
TN content by ELISA.
Further experiments investigated selected factors over a range of different
concentrations to examine whether there was a dose response effect on




Non-sterile 96 well trays were coated overnight, at 4°C (or for 2h at 37°C)
with extracellular matrix proteins at concentrations ranging from 1 to
40|igml-i in PBS. All proteins were plated into quadruplicate wells. To
take into account non-specific binding to protein 1% BSA solution (in
PBS) was used as a control. After coating the plates were washed in PBS.
Non-specific adherence to plastic was blocked by incubation for 90 min in
0.1% BSA solution.
Cells were harvested in a small amount of trypsin to produce a single cell
population, and labelled with chromium (51Cr) as described by Brunner et
al. (1976). The cells were centrifuged at 2000 rpm and resuspended in 200
pi of DMEM (+ 10 % FCS). An isotonic solution of 5iCr sodium chromate
(90 mCi) was added to the cell suspension and incubated for lh at 37°C,
with occasional mixing. The cells were centrifuged and washed 3 times in
serum-free media to remove traces of ECM proteins and serum. An
aliquot of cells was counted on a haemocytometer. Cells were then
diluted to 3 xl05 per ml. Aliquots (50 pi) were added to each well and to
counting tubes as the "input" count.
After incubation at 37°C for 2h, plates were washed twice by gently
submerging the plate in PBS supplemented by cations (1 mM Ca/0.5 mM
Mg). Plates were then cut into individual wells and counted in a gamma
counter.
% adhesion was calculated as described by Marshall et al. (1995)
mean count -mean BSA count \ ^
•—; ; x 100mean mput count )
% standard deviation was calculated as
( s.d absolute \ _ ,, .




Sterile 48 well trays were coated with ECM proteins in duplicate wells as
described in 2.8(i). Cells were harvested to give a single cell population
and washed 3 times in serum-free media. An aliquot was counted and the
cells were diluted to 1.5 xlO5 per ml. 200|il were added to each well and
the tray was incubated at 37°C for 2h. The cells were fixed in 10%
formalin, examined and photographed under phase contrast microscopy.
(iii) Migration Assay
Migration assays were performed in 8(im-diameter pore size Transwell
chambers in a method adapted from Mould et al. (1994). The undersurface
of the polycarbonate membrane was coated with various concentrations
of ECM proteins by sitting the insert in the relevant protein solution for 1
h at 37°C. The protein solution was removed and the membranes were
washed in PBS. Cells were harvested to produce a single cell suspension
of 4 x 105 cells/ml in serum-free DMEM containing 1% BSA. Aliquots of
the cell suspension (Ix 105) were added to the upper chamber of the
Transwell and 500 pi of the same media was added to the lower chamber.
The cells were incubated at 37°C for 48 h in a humidified incubator and
then cells were either fixed in 10% formalin and stained with 0.1 % crystal
violet, or trypsinised (with equal volumes of trypsin on each side of the
membrane) and counted on a coulter counter.
With the transwells stained, the cells on the upper surface of the
membrane were removed using a cotton bud. The under surface of the
membrane was examined under a microscope and 3 random fields were
counted using a graticule eyepiece. Migration was expressed as cells per
high powered microscope field.
The trypsinisation allowed cells on both sides of the membrane to be
counted and migration was expressed as the percentage of cells which had
passed through the membrane
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2.2.9 Fluorocytometric analysis of integrin receptors.
Cells were harvested using trypsin, spun at 2000 rpm and incubated with
fresh DMEM (+ 10% FCS) for 30 min at 37°C to allow them to recover
from the harvesting process. Approximately 5 xlO5 cells were required for
each antibody to be used and the aliquots of cells were washed once in ice-
cold PBS followed by ice-cold PBS containing 1% FCS (v/v) (PBS/FCS).
The cells were incubated for 30 min with primary antibody diluted in
PBS/FCS. As a negative control an aliquot of cells was incubated with
PBS/FCS. After washing in PBS/FCS, 100 pi of FITC-conjugated sheep-
anti-mouse immunoglobulin (ShAM/FITC) diluted 1:20 in PBS/FCS was
added to each tube. The cells were incubated on ice for 30-60 min, washed
twice in cold PBS and resuspended in PBS (1 ml). The suspension was
analysed on a flow cytometer, which measured the green fluorescence
produced by the FITC-conjugated secondary antibody.
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Chapter 3
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Chapter 3
Tenascin expression in primary ovarian tumours.
TN has been found to be expressed in the stroma of many solid tumours
and also in some normal tissues, including ovary, but has not previously
been studied in ovarian tumours. This is the first study to investigate the
expression of TN, both at the level of protein and RNA, in a series of
malignant, borderline and benign ovarian tumours.
3.1 Protein expression
The distribution of TN protein in sections of ovarian tumours was
examined by immunohistochemistry.
3.1.1 Optimal conditions for immunohistochemistry
The expression and distribution of TN in ovarian tumours was defined
by use of the mouse anti-human TN monoclonal antibody obtained from
DAKO. This antibody was raised against TN secreted by the U251 glioma
cell line which expresses both large and small isoforms of TN and is
reported not to cross react with fibronectin or EGF; this was verified by
ELISA (as described in section 4.2.1). Initial experiments using paraffin
fixed tumours failed to produce any staining; frozen sections of human
ovarian tumours were used in subsequent studies. The optimal antibody
concentration was determined to be a 1:50 dilution of the stock antibody;
when compared with 1:100 and 1:25 dilutions of the antibody, this
concentration provided the most economical use of the antibody whilst
saturating the antigen.
For all samples a control section without primary antibody showed
absence of staining. As an additional control, in a smaller number of
samples, the specificity of the antibody was verified by addition of pure
TN to the primary antibody, which totally abolished staining.
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3.1.2 Tenascin staining distribution
The presence of TN was investigated by immunohistochemistry in 50
primary ovarian tumours (32 malignant, 7 borderline and 11 benign) and
1 normal ovary. Complete details of these tumours are shown in table 3.1
TN staining was observed in 44 of the 50 tumours at variable levels (table
3.1). Whilst all staining was in the extracellular space, the staining
pattern could be classified as either focal or diffuse.
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Table 3.1 a Histology and TN staining of borderline and benign tumours
Sample code Histology Staining pattern Stromal
intensity
Borderline
032 serous stromal +
054 mucinous stromal +
081 mucinous negative -
102 mucinous negative -
125 mucinous stromal +
131 mucinous negative -
161 serous stromal + +
Benign
004 thecofibroma focal -
013 fibroma focal -
053 mucinous focal -
078 cystadenoma focal -
090 fibroma negative -
100 mucinous focal -
138 mixed stromal +
147 fibroma focal -
151 teratoma focal -
166 mucinous focal -
168 fibroma negative -
This table shows the histology, TN staining pattern and intensity of
stromal staining in benign and borderline ovarian tumours. TN staining




















































































































































































































































































































In the section of normal ovary the observed staining was limited to a fine
line around the smooth muscle cells of blood vessels with negligible
reaction in the surrounding ovarian stroma (figure 3.1). Where the TN
staining in tumour sections was classified as focal the immunoreactivity
was confined to structures such as blood vessels, as in the normal ovary
(illustrated in figure 3.2).
In sections demonstrating diffuse staining, in addition to the perivascular
staining, TN expression was observed throughout large regions of the
stroma (figure 3.3).
Figure 3.1 Normal ovary
Frozen section of normal ovary immunohistochemically stained with
anti-human TN antibody. (Magnification= xl25). Arrows indicate specific
immunostaining in blood vessels
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Figure 3.2 Benign tumour
Frozen section of benign tumour immunohistochemically stained with
anti-human TN antibody. (Magnification= xl25). Arrows indicate specific
immunostaining in blood vessels
Figure 3.3 Malignant tumour
Frozen section of malignant tumour immunohistochemically stained
with anti-human TN antibody. (Magnification= xl25). Arrows indicate
specific immunostaining
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The intensity of such staining was classified as strong, moderate or weak.
Heterogeneity was observed within sections of individual tumours and
where it was observed the score allocated was based upon a combination
of area stained and intensity of the reaction. Sections scored as strongly
staining had high intensity staining over 50 to 100 % of their stroma.
Moderately staining sections demonstrated a lower intensity of staining
over 50 to 100% their stroma or higher intensity staining over 25 to 50%.
Weakly staining tumours either demonstrated a low intensity of staining
over their stroma, or only showed staining at epithelial mesenchymal
junctions (less than 25%). The incidence and intensity of diffuse stromal
staining is shown in table 3.2.
Table 3.2 TN Staining in Ovarian Tumours,
a) Incidence of Stromal Staining.
Stromal Staining
negative positive
Benign (n=ll) 10 1
Borderline (n=7) 3 4
Malignant (n=32) 6 26
b) Intensity of Stained Stroma
Staining Intensity
negative weak moderate strong
Benign (n=ll) 10 0 1 0
Borderline (n=7) 3 3 1 0
Malignant (n=32) 6 10 10 6
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Both the malignant and borderline tumours showed a significantly
greater incidence of diffusely stained stroma when compared to the
benign tumours (p<0.0001 and p=0.038 respectively, by Fisher's exact test).
There was no significant difference between malignant and borderline
tumours, but numbers were small. In terms of intensity of diffuse
staining, the majority of the malignant tumours showed moderate to
strong staining while 3 of 4 stained borderline tumours displayed only a
weak reaction. Examples of strong staining were only observed amongst
the malignant tumours.
No significant associations were observed between TN expression and
histology, stage or grade of malignant tumours, but numbers in the
subgroups were often small. The distribution of TN staining in relation to
the parameters of histological type, clinical stage and grade is shown in
tables 3.3 a-c.
Table 3.3 a
Relationship between stromal TN expression and histological type
Stromal Staining
strong moderate weak negative
serous 3 3 6 1
endometrioid 3 4 2 3
clear cell 0 2 0 1
mucinous /mixed
mesothelial tumours
0 2 2 1
These data are not suitable for chi squared analysis, as numbers within
the categories are too small. When the groups are subdivided into focal or
diffuse staining and compared using Fisher's test, no significant




Relationship between stromal TN expression and stage
Stromal Staining
strong moderate weak negative
I/H 2 2 2 3
m/IV 3 8 6 2
These data were also analysed by Fishers exact test and the TN
distribution showed no significant association with clinical stage (stage
I/II vs stagem/IV p value =0.29).
Table 3.3c
Relationship between stromal TN expression and grade of differentiation
Stromal Staining
strong moderate weak negative
well 1 0 10
moderate 1 5 13
poor 4 4 7 2
Again data was analysed by Fisher's exact test and no significant
associations were observed (moderate vs poor p=0.7)
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Omental metastases were available from 7 of the malignant tumours; all
were positive and showed a similar pattern of staining to their
counterpart primary tumour with strong stromal staining around the
nests of tumour cells (figure 3.4).
Figure 3.4a Tumour
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Frozen section of paired tumour and omentum immunohistochemically
stained with anti-human TN antibody. (Magnification= x!25)
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3.2 Tenascin RNA Expression in Primary Ovarian Tumours
In other tumour types TN RNA has been examined using northern
blotting techniques (Borsi et ah, 1992; Ibrahim et al., 1993). Siri et al. (1991)
developed PCR primers within the region of TN's FN type III repeats.
These primers are capable of detecting multiple splice forms of TN RNA,
and the advantage of using RT-PCR is that smaller quantities of RNA are
required than in northern blotting.
3.2.1 Preparation of RNA samples and validation of results
RNA was prepared from 12 malignant tumours (5 serous and 7
endometrioid) and 6 benign tumours (2 mucinous cystadenomas, 3
fibromas and 1 teratoma). These tumours were all samples which had not
previously been through freeze-thaw cycles, to decrease the risk of the
RNA being degraded. The RNA integrity was examined on an RNA
formaldehyde gel, an example of which can be seen in figure 4.5. The
RNA was reverse-transcribed to DNA and amplified using PCR. After
electrophoresis of the PCR mixture, multiple bands could be visualised.
These included bands with apparent molecular weights at 284, 556, 1651
and 1924 bp, corresponding to products identified and sequenced by Siri et
al. (1991). In addition to these bands other products were visible, notably
at approximately 490 bp and 750 bp. In all samples tested the smallest band
(284 bp) was detected and its presence was used as an internal positive
control. As an additional control samples were amplified with
primers to the house keeping gene, hypoxanthine-guanine
phosphoribosyltransferase (HPRT); absence of this RNA usually indicated
degradation of the sample which was consequently discarded.
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In order to help characterise the bands the DNA was transferred to
membranes using alkaline transfer and probed with a series of internal
oligonucleotides designed to distinguish the different isoforms. The
position of these oligonucleotides in the TN monomer is illustrated in
figure 3.5. Probing with oligonucleotide 5 confirmed the authenticity of
the products, while the oligonucleotides A4, B and C distinguished the
PCR products by identifying which fibronectin type III repeats they
contained. Oligonucleotide B hybridises with all bands except the 284 bp
form, which does not contain FN type HI repeat B, while oligonucleotides
A4 and C only hybridise with isoforms which contain FN type HI repeats










This schematic diagram of the FN type III repeats of TN indicates the
region of alternative splicing (filled boxes) and shows the position of the
PCR primers TNI and TN2 on the periphery of this region. The PCR
products previously identified by Siri et al. (1991) are shown with their
length in base pairs. The position of the oligonucleotides used to probe
the PCR products is also indicated (•). Within the text the probes are
referred to as oligonucleotide 5, A4, B and C according to the FN type III
repeat in which they are found.
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3.2.2 Incidence of different Tenascin RNA isoforms in ovarian tumours.
Examples of gels showing TN PCR products can be seen in figure 3.6.
Whilst multiple RNA isoforms were detected in all the tumours
investigated, incidence of the different molecular weight bands varied
between tumour types. The 284 bp band appeared to be a constant feature
of all the tumour samples, while the relative proportions of the other
bands varied between tumours. The bands of~490 and 556 bp were present
at a higher intensity than the lower molecular weight form in 9 of the 12
malignant samples, the exceptions being HOV 008, HOV 015 and HOV
132. Of the benign tumours the only sample with a relatively high
intensity of the -490 and 556 bp bands was HOV 151. The sample of
normal ovary appeared to express the same pattern of isoforms as the
benign samples. The occasional appearance of double bands at the 284 bp
position is likely to be artefactual as the expression of the doublet was not
consistent within duplicate samples.
The gels shown in figure 3.6 were transferred to membranes and probed
with the oligonucleotides designed to distinguish the different RNA
isoforms. Examples of these probed membranes can be seen in figures 3.7
to 3.10. Figure 3.7 demonstrates that all the sizes of bands observed on the
gels were detected by the specific internal oligonucleotide, providing
evidence for the specificity of the reaction. From the PCR gels and the
membranes probed with oligonucleotide B (an example of which is
shown in figure 3.8) it is apparent that two of the RNA species (-490 and
556 bp) show a distribution which is limited more to malignant ovarian
tumours than benign. The presence of these bands as the predominant
RNA species is noted in table 3.4. Whilst the intensity of bands can not be
compared directly between tumours, because of the non-quantitative
nature of the PCR reaction, the relative intensity of the bands within each
tumour sample may be compared across samples.
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In 9/12 (75%) malignant tumours there was increased intensity of the
-490 and 556 bp bands, compared to the 284 bp band. In only 1/6 (17%)
benign tumours were these two bands present at relatively high intensity;
in the majority of benign tumours and the normal ovary sample these
bands were either totally absent or greatly reduced compared to the 284 bp
species. The benign tumour which did contain the -490 and 556 bp bands
was the teratoma. There is a statistically significant difference between the
malignant and benign expression patterns (75% versus 17%), giving a
p value of 0.043 by Fisher's exact test.
The number of tumours analysed by RT-PCR was small (18) and no
correlation was observed between the isoforms expressed and the pattern
and level of TN immunostaining.
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Malignant tumours
171 091095 149 069 132 183 008 014 019 122 015
Benign tumours
147 151 013 078 090 053
Figure 3.6 RT-PCR analysis of TN in ovarian tumours
1.4 % agarose gels containing TN PCR products. This figure contains
combined data from multiple PCR analyses, all tumours tested in this
study are included in the figure. The lowest molecular weight splice
variant can be observed in all samples. The bands of -490 and 556 bp are
present at relatively high intensity in the malignant tumours, with the
exceptions of tumours 008, 015 and 132. The only benign tumour with
relatively high intensity of the -490 and 556 bp bands is sample 151.
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Figure 3.7 Probing of TN PCR products with oligonucleotide 5
A PCR gel containing samples of malignant and benign ovarian tumours was
transferred to a nylon membrane and probed with oligonucleotide 5, which is
capable of detecting all the RNA isoforms amplified by the PCR primers. The
arrow indicates the 284 bp band. Lanes 1-5 contain malignant tumours (HOV 183,
HOV 069, HOV 014, HOV 091, HOV 171); lanes 6-8 contain benign tumours (HOV
013, HOV 147, HOV 078); lane 9 contains normal ovary.
Bands are compared within each lane rather than between lanes.
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Figure 3.8 Probing of TN PCR with oligonucleotide B
Probing the membrane with oligonucleotide B detects all but the smallest
isoform of TN and illustrates most clearly illustrates the difference
between the malignant and benign samples. Arrows indicate the 556 and
-490 bp bands. Lane 1 contains normal ovary; lanes 2-5 contain benign
tumours (HOV 078, HOV 147, HOV 013); lanes 6-9 contain malignant
tumours (HOV 171, HOV 091, HOV 014, HOV 069, HOV 183).
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Figure 3.9 Probing of TN PCR products with oligonucleotide A4
This oligonucleotide can only detect splice variants which contain FNtype III repeat A4. This membrane, was probed with this oligonucleotideafter being probed and stripped twice before. Although background levelsare higher, it can be seen that only higher molecular weight bands reactwith this probe. Lane 1 contains normal ovary; lanes 2-5 contain benigntumours (HOV 078, HOV 147, HOV 013); lanes 6-9 contain malignanttumours (HOV 171, HOV 091, HOV 014, HOV 069, HOV 183).
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Figure 3.10 Probing of TN PCR products with oligonucleotide C
This membrane contains a different group of malignant and benign
tumours to the previous three figures. Oligonucleotide C detects only
isoforms containing FN type III repeat C. Lanes 1-4 contain benign
samples (HOV 078, HOV 090, HOV 053, HOV 147); lanes 5-8 contain
malignant tumours (HOV 183, HOV 132, HOV 069, HOV 008). One major
band can be observed in most of the samples on the membrane this
corresponds to the full TN transcript.
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Table 3.4
Expression of TN RNA isoforms in ovarian tumours
Sample Histology Predominant isoform
Malignant tumours
008 serous 284 bp
014 endometrioid -490/556 bp
015 endometrioid 284 bp
019 serous -490/556 bp
069 serous -490/556 bp
091 serous -490/556 bp
095 endometrioid -490/556 bp
122 endometrioid -490/556 bp
132 endometrioid 284 bp
149 endometrioid -490/556 bp
171 endometrioid -490/556 bp
183 serous -490/556 bp
Benign tumours
013 fibroma 284 bp
053 mucinous 284 bp
078 mucinous 284 bp
090 fibroma 284 bp
147 fibroma 284 bp
151 teratoma -490/556 bp
Normal ovary 284 bp
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3.3 Association of tenascin expression with growth factors, hormones and
their receptors.
In other tumour types the expression of TN has been shown to correlate
with a number of other factors. The most widely reported correlation is
that with the growth factor TGF-fii (Walker et al., 1994). Vollmer et al.
(1994) also demonstrated that hormones can effect the expression of TN.
Data examining the expression of TGF-fi's, oestrogen and progesterone
receptors and other growth factors was available for many of the
malignant tumours examined for TN distribution. These data were
investigated to identify any statistically significant correlations between
TN protein expression and the factor.
3.3.1 Tenascin expression related to TGF-fi mRNA expression.
A subgroup of 23 malignant tumours had previously been analysed for
expression of TGF-fi isoforms by RNAse protection assay as described by
Bartlett et al. (1992). These data are illustrated in table 3.5 along with the
TN protein distribution for each sample. The numbers of benign and
borderline tumours were too small to develop an analysis.
Sample RNA extracts were considered positive for each TGF-fi isoform
when a band of the appropriate length was observed in the presence of a
positive transcript for control actin.
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Table 3.5
Expression of TN and the TGF-fi family in malignant ovarian tumours
Sample TN intensity TGF-fi isoform expression
TGF-fii TGF-C2 TGF-C3
002 + + + + + +
006 - + - +
008 + + - +
014 ++ + + +
015 + - - +
019 + + + + - -
020 - - + -
021 ++ + + -
069 + + + + + +
072 ++ + + -
077 ++ + + +
095 + + + - + -
096 - - + -
104 - - + +
109 + - + +
117 + + + -
122 ++ + + -
124 ++ + + +
132 + + + + + +
134 - + - -
137 + - + -
148 + - - -
149 ++ - + -
This table illustrates the expression of stromal TN and TGF-fi's in a series
of 23 malignant ovarian tumours. The intensity of stromal TN expression
is scored as strong (+++), moderate (++), weak (+) or negative (-). TGF-fi
isoforms are either present (+) or absent (-).
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Of the 23 tumours examined, 14 expressed TGF-fii mRNA, 17 expressed
TGF-C2 mRNA and 13 expressed TGF-C3 mRNA. To examine the
co-expression of TN with these TGF-fi isoforms the tumours were
divided into two groups; those with no/weak stromal expression of TN
and those with moderate/high levels of stromal TN (table 3.6).
Analysis by Fisher's exact test showed that there was a statistically
significant relationship between expression of TGF-fii and high levels of
stromal TN expression (p value = 0.036). TGF-fi2 showed a similar trend








High TN (++/+++) 10 2
p=0.036
Low TN (+/-) 4 7
TGF-fi2 expression
Positive Negative
Fligh TN (++/+++) 11 1
p=0.069
Low TN (+/-) 6 5
TGF-£>3 expression
Positive Negative
High TN (++/+++) 7 5
p=1.00
Low TN (+/-) 6 5
p-values by Fisher's exact test
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3.3.2 Tenascin expression related to other parameters
Data, relating to the ovarian tumours, were available for a number of
other factors. For analysis, the TN staining was again divided into those
tumours expressing strong (+++/++) stromal TN and those with
negative/weak stromal TN expression.
(i) Oestrogen receptor
The levels of oestrogen receptor were measured by enzyme-immunoassay
by Dr Tony Hawkins in the Department of Surgery, Royal Infirmary,
Edinburgh. The distribution of the receptor levels, in relation to the level
of stromal TN staining is illustrated in figure 3.11.
+ 4-
+++
TN stromal staining intensity
Figure 3.10 Relationship between TN expression and oestrogen receptor
levels.
The points on this graph represent the level of oestrogen receptor in
individual tumours, measured in fmol/mg of protein. No significant
relationship was observed between the level of oestrogen receptor




The levels of progesterone receptor were also measured by enzyme
immuno-assay by Dr. Tony Hawkins. Figure 3.12 illustrates the
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TN stromal staining intensity
Figure 3.12 Relationship between TN expression and progesterone
receptor levels.
Each point on this graph represents the level of progesterone receptor in
an individual tumour, expressed in fmol/mg of protein. No significant
relationship was revealed between levels of progesterone receptor and
TN staining (p value=0.49 by Kruskel-Wallis test).
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(iii) EGF,TGFoc and EGF receptor mRNA
The presence of mRNA for EGF, TGFa and EGF receptor was measured by
RT-PCR (Bartlett et al. 1996). Again analysis by Fisher's exact test
demonstrated no statistically significant correlation with any of these
factors.
Table 3.7
Relationship between TN expression and growth factors.
EGF expression
Positive Negative
High TN (++/+++) 2 8
p=0.35
Low TN (+/-) 4 5
TGF-a expression
Positive Negative
High TN (++/+++) 5 5
p=0.14
Low TN (+/-) 1 8
EGF receptor expression
Positive Negative
High TN (++/+++) 5 5
p=0.65
Low TN (+/-) 3 6
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Chapter 4
Tenascin expression in ovarian cell lines
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Chapter 4
Tenascin expression in ovarian cell lines
As described in the previous chapter TN is expressed in the stroma of
malignant ovarian tumours at a higher level than in normal ovary or
benign tumours. Previous studies of non-ovarian systems have indicated
that fibroblast and some epithelial cells are capable of producing TN. To
help determine which cell types produce TN, experiments were
undertaken using ovarian carcinoma and fibroblast cell line models. This
chapter describes the expression of TN protein and RNA in human
ovarian fibroblast and carcinoma cell lines.
4.1 Characterisation of cell lines
The fibroblast cells used in these experiments were derived from the
ascites of patients with ovarian cancer. The PE012 and PE027 cells were
from a patient with serous cystadenocardnoma. The PE09 cells were from
a patient with adenocarcinoma (unclassified histology) and data was not
available for the PE013 cells. The frozen ascites samples were recovered
from liquid nitrogen and transferred to tissue culture flasks; the cells were
refed with fresh media after 2-4 h so that only the attached cells remained.
The fibroblast cells are thus selected on the basis of their rapid attachment
to tissue culture plastics. Once the cultures were established, after 1-2
passages, multispot slides were made and immunocytochemistry was
used to compare the fibroblast cultures with the original ascites
population. Ascites fluid from ovarian cancer patients usually contains
fibroblasts, macrophages and often tumour cells. Antibodies were
therefore chosen specifically to detect these cell types (leucocyte common
antigen, epithelial membrane antigen and fibroblast antigen); a range of
dilutions was used to first determine the optimum antibody
concentration. Control spots were treated with no primary antibody
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The original ascitic cell population for the cell line PE012 consisted
predominantly of leucocytes with a smaller proportion of fibroblasts and
very few epithelial cells. The proportions of these cells was estimated to
be 85% leucocytes, 10% fibroblasts and 5% epithelial cells. In contrast
when the cells had been cultured to allow selection of the fibroblast
population, few cells remained which demonstrated staining with the
antibodies to common leucocyte antigen or epithelial membrane antigen.
Most of the cells did stain with the fibroblast antibody. It was estimated
that the final population was over 99% fibroblasts. Subsequent culturing
was designed to maintain and improve upon this level of purity, by
discarding cells which did not detach rapidly upon trypsinisation. The
three other fibroblast cell lines (PE09, PE013 and PE027) were observed in
culture to consist of cells with a morphology similar to that of the PE012
cells which stained only with the fibroblast antibody.
Examples of the staining observed in multispots can be seen in figures 4.1-
4.3
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Ascites demonstrating positive staining with leucocyte common antibody
(magnification = x400). Fibroblast culture demonstrating no stained cells
with the same antibody (magnification = x400).
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Figure 4.2 Immunocytochemical staining of multispot slides with
fibroblast antibody.
Relatively few cells on the slide containing ascites stain positively with
fibroblast antibody (magnification = x400), while the fibroblast culture
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Relatively few cells on the slide containing ascites stain positively
withepithelial membrane antibody (magnification = x400) and the
fibroblast culture demonstrates no staining with the same antibody
(magnification = x400).
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4.2 Measurement of Tenascin by ELISA
The amount of TN secreted into the media of cultured cells was
measured by an ELISA.
4.2.1 Validation of ELISA
The ELISA was optimised, before it was routinely used to measure TN
content in samples.
(i) Antibody concentration
The antibody used was the mouse monoclonal anti-human TN antibody,
which had previously been used for the immunohistochemical staining
of the primary ovarian sections. In order to determine the optimal
concentration of antibody to use in the assay, dilutions of standard TN
(ranging from 0.125 to 32 ng of TN per well) were incubated with varying
concentrations of the antibody, diluted in phosphate buffered saline
containing tween (PBS-T). The absorbance readings from the assay were
plotted and are illustrated in figure 4.4. Concentrations of antibody,
ranging from 1:10 to 1:80 dilutions of the stock solution, produced
parallel straight lines of absorbance versus TN content, down to the level
of 0.5 ng per well. Lower concentrations of antibody (1:160 to 1:640)
produced similar straight lines with a steeper gradient; however the lines
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Figure 4.4 Titration of antibody concentration for ELISA
In the light of these results the concentration of antibody chosen to be
used in further assays was a 1:160 dilution. This was the concentration of
antibody that produced a steep gradient of seperation over the range of
standards used in the assay, clearly discerning different amounts of TN
down to 0.5 ng per well.
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(ii) Cross reactivity
The cross reactivity of the antibody was examined using fibronectin and
EGF, because of TN's homology with these proteins. The antibody did not
produce a colorimetric response over and above background values with
fibronectin or EGF, at amounts between 15 and 2000 ng/well. This is
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Figure 4.5 Cross reactivity of ELISA with TN, fibronectin (FN) and EGF
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Initial experiments showed that media containing serum cross reacted
with the antibody. A sample of media containing 10% foetal calf serum
when assayed in the ELISA, appeared to contain 46 ng of TN per ml.
When samples of conditioned media were corrected for this amount of
TN most appeared to contain very little or no TN, whereas the same cell
types cultured in serum free conditions were seen to secrete measurable
levels. It therefore appears that serum contains a factor, possibly bovine
TN, which reacts with the anti-human TN antibody and masks the
human TN secreted into the media by the cell lines.
It was therefore decided that cells to be used in the assay should be grown
in serum-free media (DMEM + HITS), which did not cross react in the
ELISA. As serum has previously been shown to be a potent inducer of TN
it is logical that to measure the "basal" level of TN secretion, cells should
be unstimulated by serum.
It was determined whether samples could be stored frozen, prior to
assaying for TN content without affecting results, by storing the samples
in polypropylene tubes overnight at -40°C. The frozen samples were
thawed and reassayed. Levels of TN were markedly lower in the samples
which had been frozen. Conditioned media from the cell lines were
therefore assayed immediately after collection.
4.2.2 Basal levels of TN secretion in cell lines
Conditioned media were collected from cell lines cultured under serum-
free conditions for 48 h. These media were then assayed by ELISA (neat
and diluted 1:2) to assess the amount of TN secreted by the cells.
The number of cells secreting into the media were counted and the
measurements of TN secretion were corrected for cell number. This was
important as the fibroblasts reached confluence with a much lower
number of cells than the epithelial cell lines. Within each assay duplicate
samples were measured and the secretion of TN was expressed as ng
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produced in the 48 h incubation period per million cells per ml of media
(ng of TN /106 cells/ml/48 h).
Media from each cell line was assayed on a minimum of two separate
occasions and the mean secretion of TN was calculated (table 4.1; figure
4.6). The 1:2 dilutions routinely assayed for all samples were shown to
dilute as expected giving an absorbance value half that of neat samples.
Table 4.1
fibroblast




PE09 519 (± 60) 2
PE012 1053 (±213) 3
PE013 584 (± 266) 2




SKOV-3 4.1 (± 2.7) 3
59M 4.1 (± 3.9) 3
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Figure 4.6 "Basal" level of TN secretion in ovarian fibroblast and
carcinoma cell lines
The bars represent the mean level of secretion from a minimum of two
experiments and the error bars show the standard error.
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The fibroblast cell lines PE09, PE012, PE013 and PE027 secreted
substantial amounts of TN into the media; at levels between 519 and 1053
ng/106 cells/ml. The ovarian carcinoma cell lines SKOV-3 and 59M
secreted approximately 4 ng/106 cells/ml, while the remaining three
carcinoma cell lines PEOl, PE01CDDP and PE04 did not produce any
measurable TN (the assay can accurately detect levels of TN as low as 2 ng
per ml conditioned media).
It can be seen from these data that under unstimulated conditions
fibroblasts secrete amounts of TN at least 100-fold greater than epithelial
cells.
Conditioned media from the breast carcinoma cell lines, MDA-MB-231,
T47D, MCF7 and ZR-75-1, were also assayed. Only the MDA-MB-231 breast
cell line produced measurable levels of TN (an average of
8.7 (± 1.2) ng/106 cells/ml). The remaining three cell lines secreted no
detectable TN.
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4.3 Tenascin RNA expression in cell lines.
The pattern of RNA transcripts for TN expressed by cell lines was
examined using RT-PCR as described previously in section 3.2. The PCR
gels produced were probed with the specific oligonucleotides also
described in that section.
4.3.1 RNA preparation and validation of results
RNA was prepared from confluent flasks of cells. These cells were
cultured in media containing 10% serum, as it proved difficult to grow
cells to the required density, for efficient RNA extraction, in serum-free
conditions. RNA was amplified from the ovarian fibroblast cell lines
(PE012 and PE027) and ovarian carcinoma cell lines (PE01,PE01CDDP,
PE04, PE014, PEA2, 2780AD, OVCAR4, SKOV-3 and 59M). Additional
RNA samples were available from breast cell lines, (MDA-MB-231, T47D,
ZR-75-1 and MCF-7). All RNA samples were prepared using tri-reagent
(for liquid samples). RNA integrity was examined on RNA formaldehyde
gels, an example of which can be seen in figure 4.7. All the samples in
figure 4.7 are intact RNA. Two clear bands can be observed which
correspond to the 18s and 28s subunits of ribosomal RNA. If an RNA
sample had been degraded these distinct bands would not have been
present and the RNA would appear as a smear down the gel.
Samples were reverse transcribed to cDNA and primers were used to
detect the house keeping gene HPRT, as a positive control (figure 4.8). The
HPRT product produced by these primers is 290 bp and can be observed as
a single band. All samples illustrated in figure 4.8 contained this band and
there was no contamination of any reagent with RNA as the negative




Figure 4.7 RNA formaldehyde gel.
1.1% formaldehyde-agarose gel, electrophoresed at 60 V for 2h. Samples 1
to 4 correspond to cell lines PEOl, PE04 and tumours HOV 033, HOV 106.
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Figure 4.8 HPRT PCR products
1.4% agarose gel containing PCR products amplified for HPRT. Lane 1
contains a molecular weight ladder, lane 2 was a negative control
containing no RNA. Lanes 3-9 correspond to RNA samples from ovarian
cell lines (SKOV-3; 59M; PEOl; PE04; PEOl CDDP; PE012; PE027). Lane 10
contains the ovarian tumour HOV 171. Lane 11 contains a different RNA
sample from PE04 and lane 12 contains PE012. Lanes 13 and 14 contain 2
samples of RNA from the breast carcinoma cell line MDA-MB-231.
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Figure 4.9 TN PCR products
Example of a typical gel from a PCR of TN. The lanes 1 to 5 contain the
ovarian carcinoma cell lines SKOV-3, 59M, PEOl and PE04; lane 5
contains PCR products from the PEOl2 fibroblast cell line; lanes 6 and 7
correspond to ovarian tumour samples HOY 091 and HOY 095.
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Figure 4.10 Probing of TN PCR products with oligonucleotide 5
The PCR products from a gel as observed in figure 4.7 were transferred to
a nylon membrane and probed with oligonucleotide 5, which is capable of
detecting all splice variants amplified by the PCR. All the bands observed
on the gels were detected by this oligonucleotide, although some of the
apparent doublets were difficult to distinguish. Lanes 1-3 contain
malignant ovarian tumours (HOV 019, HOV 095, HOV 091), lane 4
contains the PE012 fibroblast cell line and lanes 5-8 contain the ovarian
carcinoma cell lines (PEOl, PE04, 59M and SKOV-3)
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4.3.2 Incidence of tenascin RNA in ovarian cell lines
When the cell line samples were amplified with the primers for TN a
wide range of expression levels and patterns was observed. Figure 4.9
shows a typical gel in which the ovarian epithelial cell lines SKOV-3,
59M, PEOl and PE04 produced bands with molecular weights of
approximately 284 bp, -490 bp and a large number of bands of
intermediate molecular weight (between 600 and 1921bp). The 556 bp
form was notably absent in the ovarian carcinoma cell lines.
The PE012 fibroblast sample produced fewer bands, although its pattern
does appear to closely resemble that seen in the 2 ovarian tumour. The
main bands in the fibroblast and tumour samples can be seen at 284 bp,
-490 bp, 556 bp, -750 bp and 1921 bp. The ovarian fibroblasts and tumours
did not produce the large number of bands of intermediate molecular
weight which were observed in the carcinoma cell lines.
The amplified DNA was transferred to membranes and probed with the
specific internal oligonucleotides described in section 3.2.1. Probing with
oligonucleotide 5 (figure 4.10) verified the authenticity of the bands
produced in the PCR reaction, as all the bands which were observed on
the original gel hybridised with this probe.
A number of other ovarian carcinoma cell lines were also examined for
TN PCR products. An additional ovarian fibroblast cell line was
examined along with RNA from breast carcinoma cell lines. These data
are summarised in table 4.2.
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Table 4.2 Summary of TN RNA expression in cell lines
Cell type Bands present (molecular weight in bp)
284 490 556 intermediate forms 1921
Ovarian carcinoma
PEOl + + - multiple +
PEOICDDP + + - multiple +
PE04 + + - multiple +
PE014 + + - multiple +
SKOV-3 + + - multiple +
59M + + - multiple +
PEA2 + + - multiple +
2780AD + + - multiple +
OVCAR4 + + - multiple +
Ovarian fibroblast
PE012 + + + -750 only +
PE027 + + + -750 only +
Breast carcinoma
MDA-MB-231 + + - multiple +
T47D - - - - -
ZR-75-1 - - - - -
MCF7 - - - - -
From the data shown on the previous pages it can be seen that both the
fibroblasts and ovarian carcinoma cell lines examined are capable of
producing multiple forms of TN RNA. The ovarian fibroblasts produce a
banding pattern strikingly similar to that observed in malignant ovarian
tumours.
It is interesting to note that the ovarian carcinoma cell lines PEOl,
PEOICDDP and PE04, which did not secrete any measurable TN into
conditioned media, appeared to produce multiple molecular weight
forms of TN RNA, i.e. the mRNA was not translated or it produced
amounts of TN protein which were less than the sensitivity of the ELISA.
The breast carcinoma cell lines T47D, ZR-75-1 and MCF7 were shown to
produce no detectable TN RNA or protein. It is also possible that
culturing the ovarian carcinoma cell lines in the presence of serum
stimulated the production of TN RNA.
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4.4 Modulation of tenascin secretion
The restricted distribution pattern of TN in human adults indicates that
control of the expression of this molecule is highly regulated. Several
growth factors, hormones and cytokines have been implicated in the
modulation of TN expression; these factors may be acting in an autocrine,
paracrine or even endocrine manner. This section describes experiments
which examine paracrine influences and potential modulating factors of
TN secretion in ovarian cell systems.
4.4.1 Co-culturing of cell lines
It was observed in the immunohistochemically stained ovarian tumour
sections that the most intense TN staining was found in the stromal
tissue adjacent to carcinoma cells (eg. figure 3.2). This pattern of staining
would be consistent with the hypothesis that the secretion of TN by
fibroblasts is stimulated by paracrine growth factors being secreted by the
tumour cells.
In order to investigate whether such a paracrine loop exists in ovarian
cell systems, ovarian fibroblasts (PE012 and PE09) were co-cultured with
the PEOl ovarian carcinoma cell line. The fibroblast and epithelial cell
populations were kept physically separated using porous tissue culture
inserts, as illustrated in figure 4.11 These inserts have a high density of





Figure 4.11 Schematic representation of the co-culturing method.
The system was co-cultured for 48 h and the media was collected and
assayed for TN content by EUSA.
The results of a typical experiment utilising both PE012 and PE09
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Figure 4.12 Levels of TN secretion in co-cultured populations of fibroblast
and epithelial cells
Data are from a typical experiment. Each bar represents the mean value
from quadruplicate wells and the error bars indicate the standard error.
The data in figure 4.12 demonstrates that PEOl carcinoma cells secreted
negligible amounts of TN, while both the PE012 and PE09 fibroblasts
when cultured alone secreted considerable amounts of TN (342 and 98
ng/106/ml respectively). When these fibroblasts were co-cultured with
the PEOl cells the level of TN secretion increased (to 432 ng/106/ml for
PE012 and 131 ng/106/ml for PE09). The co-cultured cell populations
secreted approximately 27% more TN than fibroblasts cultured alone.
This experiment has been repeated and whilst the absolute values of TN
secretion vary between experiments the degree of stimulation in the co-
cultured populations remains the same.
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In the mixed populations only the fibroblast cell number was taken into
account, as the PEOl cells were shown to secrete only background levels
of TN. It is possible that the fibroblasts may have secreted factors which
induced the PEOl cells to secrete TN, however this is unlikely as further
experiments (section 4.4.2 (ii)) indicate that PEOl cells, even in the
presence of TN stimulating factors, do not secrete levels of TN which
would account for the differences observed in these co-culturing
experiments.
In order to examine whether the increase in TN secretion in co-cultured
populations was statistically significant, the amount of TN in the
conditioned media containing fibroblasts alone was compared with the
media from fibroblasts co-cultured with the epithelial cells using a paired
statistical test. The data from experiments on 3 separate occasions was
combined for analysis. The wells containing single and co-cultured
populations were paired according to their position on the 24 well tray,
with adjacent wells being analysed together.
The increase in TN secretion was observed in 11 of the 12 co-cultured
populations. This was statistically significant with a p value of 0.0034, as
tested by a Wilcoxon signed rank test.
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4.4.2 Potential modulating factors of TN secretion.
A range of growth factors, hormones and cytokines was chosen on the
basis of their modulations of TN secretion in other cell types and also on
their effects on ovarian cell behaviour. The concentrations used for the
initial screening had previously been established to be effective in
ovarian cells.
Table 4.3 Concentrations used of potential modulating factors
Factor Concentration Reference
fi-oestradiol (E2) 10"10 M Langdon et al., 1990
Human chorio gonadotropin (HCG) 10 IU/ml Langdon S.P.
unpublished data
Follicle stimulating hormone (FSH) 0.1 IU/ml Langdon S.P.
unpublished data
Insulin-like growth factor-I (IGF-I) 10-8 M Bartlett et al., 1995
Insulin-like growth factor-H (IGF-II) 10"8 M Bartlett et al., 1995
Interferon y (IFN) 10 IU/ml Langdon S.P.
unpublished data
Transforming growth factor-fii (TGFfi-[)2.4 x 10*9M Pearson et al., 1988
Progesterone (PG) 10"10 M Langdon S.P.
unpublished data
Endothelin-1 (ET-1) 10-8 M Moraitis et al., in
press
These factors did not cross react in the ELISA for TN.
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(i) Modulation of fibroblast TN secretion.
The effects of adding the factors in table 4.2 to serum-free cultures of
fibroblasts were investigated. The results of a typical experiment are
shown in figure 4.13.
Factor
Figure 4.13 Modulation of TN secretion in the PE012 fibroblast cell line
These data represent the absolute values of TN secretion from a single
experiment. Each bar shows the mean value of triplicate wells and the
error bars represent standard deviation.
In this experiment stimulation of TN synthesis was observed upon
addition of IGF-II, TGF-fii and progesterone. Addition of HCG, FSH, IFN
and IGF-I produced inhibition of TN secretion. Statistical analysis using
Dunnett multiple comparisons test demonstrated that TGF-fii was the
only factor to produce a significant effect with a p value less than 0.01.
Levels of TN secretion after addition of oestrogen and endothelin were
not different to control levels. This experiment was repeated and the data
from those factors which were found to produce a consistent effect are
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illustrated in figure 4.14.
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Figure 4.14 Percentage modulation of TN secretion in the PE012 fibroblast
cell line.
These data represent the mean values from a minimum of two
experiments. TN secretion is expressed as the percentage of the control
level of secretion with the control level being equal to 100%. For an
individual experiment each factor was assayed either in quadruplicate or
triplicate. The error bars represent the standard error. All these factors
produced an effect significantly different from control levels
TN secretion in the PE012 ovarian fibroblast cell line was stimulated by
IGF-E (115%), progesterone (142%) and TGF-fii (257%). TGF-fii produced
the largest induction of TN with a mean 2.5 fold increase. While the
effects of IGF-H and progesterone were relatively small they consistently
stimulated TN secretion above control levels. Conversely, TN secretion
was inhibited by the gonadotrophins, HCG (56%) and FSH (59%) and by
interferon (65%). HCG produced the greatest effect decreasing TN
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Figure 4.15 Modulation of TN secretion in the PE027 fibroblast cell line
This graph represents the absolute values of TN expression in the PE027
cell line, each bar shows the mean level of secretion from duplicate wells
and the error bars show the standard deviation.
Similar results, to those observed in the PE012 cell line, were obtained
with the PE027 cell line, although it produced less TN under basal
conditions. There was a 2.8 fold induction in TN secretion upon addition
of TGF-fi i (although this was not significantly different from the control
in this experiment).
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(ii) Modulation of carcinoma cell TN secretion
Although most of the carcinoma cells tested failed to secrete measurable
levels of TN in serum-free conditions, the range of factors was also tested
against the PEOl ovarian carcinoma cell line and the MDA-MB-231 breast
carcinoma cell line, which does secrete measurable levels of TN.
60 "I
Figure 4.16 Modulation of TN secretion in the breast carcinoma cell line
MDA-MB-231
This graph illustrates absolute values of TN secretion by the MDA-Mb-231
breast carcinoma cell line. Each bar represents the mean level of secretion
from triplicate wells and the error bars represent the standard deviation.
The line indicates the control level of secretion for reference.
The only factor of those tested to alter the level of secretion, in MDA-MB-
231 cells, was TGF-fii which increased the levels of secreted TN by a factor
of 2.5 (p = < 0.01 by Dunnetts multiple comparison test).
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The factors TGFfii, EGF, TGFa and IGF-II were also tested against the
PEOl ovarian carcinoma cell line, which secretes no measurable TN in
serum-free conditions. None of these factors increased the level of TN to
a detectable level. This does not definitively demonstrate that PEOl cells
never produce TN, although they do not appear to be capable of secreting
levels which are comparable with those produced by ovarian fibroblasts,
or the breast cell line MDA-MB-231.
4.4.3 Modulation of TN secretion by TGF-fii
In PEOl2 fibroblasts, PE027 fibroblasts and MDA-MB-231 breast cancer
cells, TGF-fii produced the largest stimulation of TN secretion of all the
factors tested. To investigate whether TGF-fii exerted its effects in a dose
dependent manner, the factor was added in a range of concentrations as
used by Pearson et al. (1988). 60 ng/ml is equivalent to the 2.4 xlO-9 M
concentration used in the initial screening.





























Figure 4.17 Modulation of TN secretion in PE012 fibroblasts by TGF-fii
This graph represents mean values of TN secretion from quadruplicate
wells. The error bars represent standard deviation.
All concentrations of TGF-fii produced a significant stimulatory response
(p values less than 0.01 by Dunnett multiple comparison test) The
maximum stimulation was observed upon addition of 10 ng/ml TGF-fii
The experiment was repeated in a modified fashion to include a 10 fold
dilution of TGF-fii. The TGF-fii is dissolved in 4mM HC1 containing BSA
(1 mg/ml), therefore this experiment contained an additional control of
serum free media containing BSA and HC1 to the same concentrations as
were found in the TGF-fi samples
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Figure 4.18 Modulation of TN secretion in PE012 fibroblasts by TGF-fii
This graph illustrates the mean values of TN secretion from
quadruplicate wells, the error bars represent standard deviation.
These data demonstrate that TGF-fii stimulates the secretion of TN in a
dose dependent manner. The effect is specific to the TGF-fi, as the
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Chapter 5.
Functional roles of Tenascin
The previous two chapters have demonstrated that TN expression is
increased in ovarian carcinomas and that ovarian fibroblasts are capable
of secreting TN into their surroundings. The secretion of TN by
fibroblasts can be increased by growth factors such as TGF-fii. This chapter
describes experiments which were conducted to assess whether TN is
functional in ovarian cell systems. Previous studies of other carcinoma
systems have indicated that TN may facilitate invasion or stimulate cell
proliferation and these properties were investigated.
5.1 Attachment of ovarian carcinoma cell lines to ECM proteins
The matrix of proteins surrounding cells not only provide structural
support, but it is now appreciated that changes in this matrix
environment can lead to altered cell morphology and behaviour, such as
increased migration and proliferation. For the matrix proteins to exert
these effects cells must physically attach to the proteins. The experiments
in this section examined the attachment of ovarian carcinoma cells to
TN, both quantitatively and qualitatively. The effects of TN were
compared with those of fibronectin, with which TN shares some
homology, and collagen IV, which is a major component of most
matrices.
5.1.1 Adhesion of cells to ECM proteins
These experiments investigated the binding of cells to ECM proteins,
using a quantitative assay in which aliquots of radiolabeled cells were
incubated in wells containing the ECM proteins; additional aliquots of
cells were placed directly into counting tubes to provide the input value.
The percentage adhesion was determined by comparing the residual
radioactivity in the wells with this input value.
96 well trays were coated with TN by incubation overnight at 4°C; the
ECM proteins fibronectin (FN) and collagen IV (CIV) were also coated
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onto the trays for comparison. Bovine serum albumin (BSA) (1%) was
used as a control to examine any non-specific protein binding; the binding
to BSA was always less than 10% of the input value, this nonspecific
binding was subtracted from all the values before the percentage adhesion
was calculated.
(i) Determination of saturating protein levels.
The majority of ECM proteins produce saturating levels of cell binding at
10 |ig/ml (JF Marshall, personal communication), however there are no
data available for the ovarian cell lines and relatively little data on the
binding properties of TN. Serial dilutions of the proteins were used to
determine the saturating concentrations for these proteins with the
ovarian carcinoma cell lines. The cell lines to be investigated were radio-
labelled with chromium and incubated in the trays for 2h to allow
attachment to the ECM proteins, before washing and counting.
The results from this experiment using the SKOV-3 ovarian carcinoma
cell line are illustrated in figure 5.1.
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Figure 5.1 Attachment of SKOV-3 cells to different concentrations of ECM
proteins
These data represent the levels of binding to collagen IV (CIV),
fibronectin (FN) and tenascin (TN).The points on this graph represent the
mean data from quadruplicate wells, error bars are not illustrated
however the percentage standard deviation was always less than 10 %
It was observed in the above experiment that as the concentration of
fibronectin and collagen IV increased adhesion on fibronectin increased
up to a plateau where 42% of the cells had adhered; collagen IV showed a
similar effect with a maximum level of 58% adhesion within the 2 hour
incubation period. The levels of fibronectin and collagen IV appeared to
reach saturating levels at 10 and 20 pg/ml respectively. Binding to TN
increased to a peak at 10 (ig/ml of protein and then the level of adhesion
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decreased. For further experiments the ECM proteins were used at a
concentration of 10 pg/ml; as binding is optimal or near optimal in most
instances.
(ii) Comparison of attachment of different cell lines to ECM proteins
The ligand preferences of the ovarian carcinoma cell lines were
investigated by plating the cells onto TN, fibronectin and collagen IV, all
at 10 |ig/ml.
The results from a typical experiment are shown in figure 5.2.
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59M SKOV-3 PEOl PE04
Figure 5.2 Adhesion of ovarian carcinoma cells to ECM proteins
The bars represent the mean value from quadruplicate wells and the
error bars show the percentage standard deviation. The ECM proteins
were used at a concentration of 10|xg/ml. (TN =tenascin; FN =fibronectin;
C IV =collagen IV).
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The SKOV-3 and 59M cell lines show a similar level of adhesion; in the
wells containing fibronectin and collagen IV around 40% of the cells
attached. In the wells containing TN, attachment was considerably less,
approximately 10% of the input value. The level of attachment of these
cells to TN was significantly different to that observed on fibronectin and
collagen IV(p=<0.001 by Tukey-Kramer multiple comparison test).
The PEOl cell line showed a different preference for the ECM proteins.
The greatest level of adhesion (29%) was observed on fibronectin with
only a slightly reduced level of binding to TN (22%); these levels of
adhesion were not significantly different from each other. The poorest
substrate for adherence of PEOl cells was collagen IV which demonstrated
only 11% adhesion; a level of binding significantly different to both TN
and fibronectin (p=<0.05 and p=<0.001 respectively by Tukey-Kramer
multiple comparison test).
PE04 cells demonstrated the lowest levels of adhesion overall, with
maximum levels of 14% seen on collagen IV. They showed the least
preference for fibronectin (6%) and slightly more binding to TN (10%).
The levels of binding to TN and fibronectin were not significantly
different to each other.
This experiment has subsequently been repeated and while the absolute
values of adhesion differ between experiments, relative amounts of
binding to the different proteins remained the same. All values were
corrected for non-specific protein binding by subtracting the level of
adhesion to the wells containing BSA (the level of attachment to BSA
was always less than 10% of the input value and was comparable to the
level of adhesion observed on uncoated plastic). Therefore, it can be seen
from these data that TN does promote the attachment of ovarian
carcinoma cells, although different cell lines have varying affinities for
the ECM proteins studied.
5.1.2 Morphology of cells on ECM proteins
The morphology of the cell lines was examined qualitatively by noting
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the appearance of the cells attached to TN, fibronectin and collagen IV, by
phase contrast light microscopy. Cells which attached well were less
retractile than those which were weakly attached. BSA was again used to
provide a control for non-specific adhesion of cells to protein; very small
numbers of cells attached to the BSA, comparable to those attaching to
uncoated well surfaces.
Figures 5.3 to 5.6 show the morphology of the four cell lines investigated
In routine culture PEOl cells do not show a large degree of spreading and
appear rounded. However, in this experiment (figure 5.3a) it was
observed that there were differences in morphology of the cells plated on
TN and fibronectin; the cells on TN appear more retractile, implying that
the have not spread out on the substrate. Fewer cells appeared to have
attached to the collagen IV and very few cells were attached to the BSA
coated surface.
As was observed in the adhesion assay, the PE04 cells showed the lowest
levels of attachment to all proteins (figure 5.4). The cells that attached on
TN appeared to be rounded and refractile with little obvious spreading
when compared to those on fibronectin and collagen IV. The lowest level
of attachment was on BSA and collagen appeared to provide the best
substrate for attachment.
The SKOV-3 cells attached and spread in large numbers on all the
proteins with the exception of BSA (figure 5.5). It was observed that cells
on TN had a different morphology to those on fibronectin and collagen
IV. The morphology on TN was best described as "spindly". This different
morphology may mean that the cells were not so firmly attached and
could explain why the level of attachment measured in the adhesion
assay was so much lower, since these cells may have been dislodged
during the washing process
59 M cells did not attach to BSA coated wells however, they attached and
spread on the ECM proteins (figure 5.6). No obvious differences in
morphology were observed between the 3 proteins.
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Figure 5.3 a Morphology of PEOl cells on TN and fibronectin
This figure illustrates the morphology of PEOl cells on TN and
fibronectin (FN) as observed under phase contrast microscopy.
(Magnification xlOO)
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Figure 5.3 b Morphology of PEOl cells on collagen IV and BSA
This figure illustrates the morphology of PEOl cells on collagen IV (CIV)
and BSA as observed under phase contrast microscopy. (Magnification
xlOO)
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Figure 5.4 Morphology of PE04 cells on TN and fibronectin
This figure illustrates the morphology of PE04 cells on TN and
fibronectin (FN) as observed under phase contrast microscopy.
(Magnification xlOO)
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Figure 5.3 b Morphology of PE04 cells on collagen IV and BSA
This figure illustrates the morphology of PE04 cells on collagen IV (CIV)
and BSA as observed under phase contrast microscopy. (Magnification
xlOO)
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Figure 5.4 Morphology of SKOV-3 cells on TN and fibronectin
This figure illustrates the morphology of SKOV-3 cells on TN and
fibronectin (FN) as observed under phase contrast microscopy.
(Magnification xlOO)
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Figure 5.3 b Morphology of SKOV-3 cells on collagen IV and BSA
This figure illustrates the morphology of SKOV-3 cells on collagen IV
(CIV) and BSA as observed under phase contrast microscopy.
(Magnification xlOO)
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Figure 5.4 Morphology of 59M cells on TN and fibronectin
This figure illustrates the morphology of 59M cells on TN and fibronectin
(FN) as observed under phase contrast microscopy. (Magnification xlOO)
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Figure 5.3 b Morphology of 59M cells on collagen IV and BSA
This figure illustrates the morphology of 59M cells on collagen IV (CIV)
and BSA as observed under phase contrast microscopy.
(Magnification xlOO)
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5.2 Migration of ovarian carcinoma cells on ECM proteins
The haptotactic motility of cells on TN, fibronectin and BSA was
measured by examining the migration of cells through porous transwell
inserts. The lower surface of the inserts were coated with each respective
protein (10 (ig/ml). The cells were added to the upper surface of the
membrane in serum-free medium. The lower compartment also
contained serum-free medium with no chemoattractants, as the assay
measured directional migration on substrate bound ECM proteins. The
cells were incubated at 37°C for 48 h, to ensure that all cells had an
opportunity to adhere to the transwell surface.
The relative proportions of cells on the under side of the transwells were
determined, in initial experiments, by counting 3 random high powered
microscope fields, as illustrated in figure 5.7a. This method was
problematic and time consuming, as the high density of pores in the
membrane made identifying cells difficult. This was overcome by staining
the cells on the underside of the membrane with crystal violet. This stain






Figure 5.7a Migration of SKOV-3 cells, by counting random fields
These data represent mean number of cells/high powered microscope
field from triplicate wells, for each well the mean number of cells was
determined by counting 3 random fields. The error bars represent
standard deviation.
Substrate
Figure 5.7b Migration of SKOV-3 cells measured by crystal violet staining
This figure shows the mean data from triplicate wells, with error bars
representing standard deviation.
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The data in figure 5.7 a demonstrates that very few cell migrated through
the transwell coated with BSA (0.43 cells/field), while relatively large
numbers of cells were found on the underside of the transwells coated
with TN and fibronectin (74 cells/field and 129 cells /field respectively)
Figure 5.7 b confirms these findings with a low level of crystal violet
staining on BSA treated filters. Higher absorbance values, corresponding
to larger numbers of stained cells, were observed in the transwells coated
with TN and fibronectin. Thus both methods for examining the number
of cells on the underside of the membrane produced similar results, with
BSA showing very low levels of migration, TN and fibronectin
promoting migration. Significantly more cells apparently migrated on
fibronectin than TN (p = <0.01 by Student-Newman-Keuls multiple
comparison test).
Both these methods are commonly used to assess migration, although
they do not take into account the number of cells remaining in the upper
compartment of the transwell. A more revealing method for assessing
migration therefore is to count cells in both the upper and lower
compartments and express migration as the percentage of cells which
have passed through the membrane. A typical result from such an







Figure 5.8 Percentage migration of SKOV-3 cells
This figure illustrates the mean percentage of cell migration from
triplicate wells.
The data in figure 5.8 shows that 2.8% (± 0.3%) of the total number of cells
migrated through transwells coated with BSA, while 19.2% (± 4.9%) of the
cells migrated on TN and migration on fibronectin was at a level of 25.3%
(± 2.1%). However, while it was observed in the SKOV-3 ovarian
carcinoma cell line that fibronectin supports a higher level of motility
compared to TN, this difference is not statistically significant. Both
proteins promote significantly greater migration than was observed on
BSA coated transwells (p = <0.01 by Student-Newman-Keuls multiple
comparison test).
The level of migration was also investigated in the PEOl ovarian
carcinoma cell line.
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Figure 5.9 Percentage migration of PEOl cells
The migration of PEOl ovarian carcinoma cells was only measured on a
single occasion. Each bar illustrates the mean percentage of migration
from triplicate wells and the error bars represent standard deviation.
It was observed that both TN and fibronectin promoted migration over
the level of BSA. TN was a more permissive substrate for PEOl cell
migration, with 8.1% (± 0.9%) of the cells migrating through the
membrane, compared with 5% (± 0.2%) migrating on fibronectin. The
level of migration on TN was significantly different to the levels of
migration on fibronectin and BSA (p = <0.05 by Student-Newman-Keuls
multiple comparison test). The general level of migration of this cell line
was lower than that found in the SKOV-3 cell line.
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5.3 Analysis of integrin expression in ovarian carcinoma cell lines
Integrins are cell surface receptors, which exist as heterodimers consisting
of an a and fi subunits. Tenascin has been demonstrated to bind to the
integrins a2fil, a8fil, a9fil, aVfi3 and aVC6. Antibodies were available
against a2fil (P1E6), aVfi3 (LM609) and aVC6 (E7P6). The antibody stock
solutions were diluted in PBS containing serum (P1E6 diluted 1:100,
LM609 diluted 1:200 and E7P6 diluted 1:10). The antibodies and their
recommended dilutions were provided by Dr J. Marshall, Richard
Dimbleby Department of Cancer Research, St Thomas' Hospital, London.




Flow cytometry analysis of ovarian cell lines using antibodies to integrins
This figure shows a typical plot of fluorescence versus cell number for
each of the four cell lines
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Figure 5.11 Profile of integrin expression in ovarian carcinoma cell lines
The median fluorescence of each cell line was assayed on two separate
occasions and the relative intensity was calculated by comparison with
the control level (control = 1.0 relative fluorescence unit). The bars in this
graph represent the mean relative fluorescence of the two experiments
with the error bars representing standard deviation.
It was observed that all 4 cell lines reacted with the antibody P1E6; this
demonstrated that they all expressed the integrin <x2fil on their cell
surface. The SKOV-3 cell line also reacted with the LM609 antibody which
is specific for the integrin aVfi3. PEOl and PE04 cells did not react with
this antibody, while the 59M cell line only showed a level of fluorescence
which was slightly elevated when compared to control levels. None of
the cell lines reacted with the E7P6 antibody and therefore they probably
do not express the integrin aVfi6.
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5.4 Effects of tenascin on proliferation of an ovarian carcinoma cell line.
Studies in other cell lines have demonstrated that TN can stimulate
growth (End et al. 1992). It was also observed that in co-culturing
experiments (described in section 4.4.1) the number of PEOl carcinoma
cells in the mixed populations was greater than in those cultured alone.
Table 5.1 Changes in PEOl cell numbers on co-culturing with fibroblasts









These cells had been cultured with fibroblasts, in serum free conditions,
for 48 h and in some cases the cell numbers were double that observed in
the separate population. This experiment was designed to examine
whether the levels of TN secreted by the fibroblast cells could be causing
this increase in cell number.
TN was added to PEOl cells at a concentration of 0.1 (ig/ml, the level
secreted by PE012 fibroblasts, and at a 10 fold increased concentration
(1 |ig/ml), to take into account the increases that may be found in the co-
culturing experiments due to local increases in concentration. EGF
(10"10 M) was used as a positive control and the control cells were grown
in serum free conditions without any additions of factors. Media were
changed and fresh factors were added on days 0 and 3. Cells were counted
on days 0,3 and 5.
The results from a typical growth experiment are illustrated in figure 5.12
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Day
Figure 5.12 Effects of TN and EGF on the growth of PEOl cells.
The points on this graph represent the mean counts from quadruplicate
wells, error bars illustrate standard deviation. This experiment was
subsequently repeated and produced consistent results.
As expected EGF stimulated the growth of PEOl cells. In comparison with
control levels, neither concentration of TN altered growth rate. This
indicated that the TN secreted by the fibroblasts cells was unlikely to alter









6.1 General expression of tenascin
This thesis includes studies on clinically derived materials from ovarian
tumours which represent the first in which TN expression was observed,
at the level of protein and RNA, in a series of ovarian tumours.
Differences were observed in the pattern of immunohistochemical
staining and species of RNA expressed, between malignant and benign
tumours.
In 26 of the 32 malignant tumours, diffuse TN staining was detected
throughout the tumour stroma. This pattern of staining was markedly
different to that observed in normal ovarian tissue and the benign
ovarian tumours. The majority of those malignant tumours showing this
diffuse stromal staining pattern, expressed moderate or strong levels of
TN. The highest intensities of stromal staining observed were found
within this group of malignant tumours.
A group of 7 borderline tumours were studied and 4 of these
demonstrated the diffuse stromal staining. This incidence of stromal TN
expression was significantly higher than that in benign tumours. Whilst
the distribution pattern in borderline tumours resembled that found in
malignant tumours, the level of intensity was generally lower in the
borderline samples with weak staining observed in 3 of the 4 tumours
with positive stroma.
Of the 11 benign tumours studied, TN staining was undetectable in 2
samples and 8 showed a pattern of protein expression which was similar
to that observed in normal ovary, with TN limited to focal expression
around blood vessels. The presence of TN in the walls of blood vessels in
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normal ovarian tissue was also noted by Tamura et al. (1993). TN has also
been shown to be a vascular component in other normal tissues (Mackie
et al., 1992). Tamura et al. also demonstrated TN staining in ovarian
structures such as regressing corpora lutea and atretic follicles; the sample
of normal ovary examined in this thesis contained none of these
structures. The benign tumour which demonstrated a moderate level of
diffuse stromal staining was classified as having a mixed histology,
consisting of cystadenofibroma/thecoma/granulosa.
These findings are comparable with those made in other solid tumours.
In prostate tissue. Ibrahim et al. (1993) found that normal adult tissue
showed only weak focal staining; they utilised the staining of blood
vessels as an internal control. 80% of the benign tumours they studied
expressed TN, the majority of this staining was focal (the TN was
expressed as discontinuous periglandular bands). Of the malignant
tumours examined 96% were positive for TN with high grade tumours
demonstrating staining of the ECM surrounding tumour cells. Although
their findings were similar to those observed in this study of ovarian
tumours the pattern in malignant prostate tumours did not differ
significantly from that in benign lesions. The findings within this thesis
are, however, consistent with those made in endometrial tumours by
Vollmer et al. (1990). They too demonstrated that in normal and benign
tissue TN expression was weak and focal, whilst in endometrial
adenocarcinoma the entire ECM of the stromal mesenchyme displayed
diffuse TN staining.
Omental metastases are formed as the primary ovarian tumours shed
cells into the peritoneal cavity; these implant on the mesothelium
covering the omentum, invade the tissue and form new stroma and
extracellular matrix. It was observed that omental metastases expressed a
strikingly similar pattern of TN expression to their primary counterparts.
Sections of normal omentum were investigated but no TN staining was
observed. However these sections were of very poor quality due to the
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difficulty in cutting the essentially fatty tissue. Ibrahim's study of prostate
cancer also examined metastases in lymph nodes, and demonstrated that
the stroma in these tumours stained intensely for TN. These data
demonstrate that the new stroma which is generated when carcinoma
cells invade a secondary tissue is also rich in TN, thus implying that TN
may be involved in the metastatic process.
The overexpression of TN in the stroma of malignant ovarian tumours
prompted further studies utilising ovarian cell lines to address the nature
of the cell types which may be capable of producing TN.
Measurements of TN secretion, by ELISA, demonstrated that ovarian
fibroblasts secrete TN into their media, while ovarian carcinoma cell lines
do not secrete measurable levels of TN. Several other studies have
demonstrated that fibroblasts are capable of producing TN (Inaguma et al.,
1988; Chiquet-Ehrismann et al., 1989). However an equal number of
studies have demonstrated that epithelial cells are also able to produce
the protein (Herlyn et al., 1991; Kawakatsu et al., 1992; Lightner et al.,
1994). Indeed Chiquet-Ehrismann (1995) states that "it was believed that
epithelial cells do not synthesise TN, whereas fibroblastic cells do. This
prejudice is certainly false... it remains to be seen whether almost all cells
may be capable of TN production given the appropriate environment and
stimuli." Most of the epithelial cell lines studied required addition of
growth factors or serum in order to produce TN; melanoma cell lines are
capable of producing TN under growth factor-free culturing conditions
(Herlyn et al., 1991), indicating constitutive expression of TN. These
studies have shown that glioma and melanoma cell lines are the only
epithelial cells capable of producing levels of TN comparable to that
found in fibroblasts. Glioma cells secrete 5-10 |ig/ml (Erickson and
Lightner, 1988) fibroblasts have been shown to secrete levels between 200-
500 ng/ml (Erickson and Bourdon, 1989).
This study demonstrated that fibroblasts are capable of secreting levels
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over 100 fold higher than the ovarian carcinoma cells in vitro. The levels
measured were comparable to those found by Erickson and Bourdon
(1989). The TN measured was secreted into the media and it is likely that
intracellular and matrix TN were not measured. Attempts were made to
measure TN in cell lysates, however, these were unsuccessful as large
amounts of non-specific background antibody binding were observed; this
was not overcome by adding blocking stages to the ELISA protocol, or
using different immulon trays. Carnemolla et al. (1992) demonstrated that
transformed cultured cells were unable to deposit TN into the matrix; any
protein they produced was secreted into the media. Conversely
untransformed fibroblasts retained 60-90% of their TN in the matrix.
These observations implied that the values of secretion of TN obtained
for the ovarian fibroblasts may be an underestimate of the true value,
whilst any TN produced by the carcinoma cells should have been secreted
into the media and therefore detected by the assay. This indicates that for
carcinoma cells to produce amounts of TN comparable to those from
fibroblasts there would have to be between a 100 fold and 1000 fold
induction of synthesis.
Within this thesis levels of TN secretion were investigated in the breast
carcinoma cell lines MDA-MB-231, T47D, MCF7 and ZR-75-1. The only
cell line to secrete detectable levels of TN was MDA-MB-231, which
secreted 8.7 ng/106 cells/ml. Lightner et al. (1994) assayed culture
supernatant from breast carcinoma cell lines by ELISA. The results
obtained in this study were compared to those found by Lightner, to
examine whether there was consistency between the two different ELISA
methodologies. Lightner et al. (1994) examined 11 breast carcinoma cell
lines and found that the MDA-MB-231 cell line was 1 of 4 breast
carcinoma cell lines which secreted detectable TN; 7 other cell lines they
examined, including T47D, MCF7 and ZR-75-1, did not secrete TN. The
level of TN they observed from the MDA-MB-231 cells (89 ng/ml) was 10
fold greater than that observed in this study . This difference is probably
explained by the presence of serum in the media used by Lightner's
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group, serum is known to be capable of stimulating TN synthesis. The
antibody used by Lightner had been determined not to cross-react with
bovine TN whereas experiments indicted that the antibody used in this
study did cross react with media containing serum. Kawakatsu et al. (1992)
in a qualitative assay, also observed that the MDA-MB-231 cells produced
immunoprecipitable TN, while the other three cell lines did not produce
any TN; their assay was carried out in serum-free conditions.
The observations on TN expression made in the clinical specimens, at the
level of protein, were also consistent with the presence of TN RNA. RT-
PCR detected TN RNA in all the tumours examined. Multiple isoforms
were detected in the samples including the products which had been
previously described by Siri et al. (1991). The forms described by Siri had
been fully characterised by sequencing and probing with oligonucleotides
with specificity equivalent to oligonucleotides 5 and B, as used in this
study; these oligonucleotides hybridised with bands containing FN type III
repeats 5 and B. The additional oligonucleotides A4 and C confirmed the
description of the FN type III repeats present in the larger isoforms as
described by Siri et al. (1991).
Although all samples examined expressed TN RNA, differences were
seen in the RNA splicing patterns between malignant and benign
tumours. All but 1 of the 6 benign tumours examined produced a pattern
similar to that found in normal ovary. In malignant tissue there was an
increased expression, particularly of the -490 and 556 bp products. Paired
samples of omental metastases were not examined as the fatty nature of
the tissue prevented efficient RNA extraction.
The band observed at -490 bp had not been previously described by Siri et
al. (1991). This band hybridised with specific oligonucleotides recognising
FN type III repeats 5 and B. The molecular weight of the band is not
sufficient for it to contain the complete form of both these repeats; this
indicates that it may be produced by internal splicing sites, or may contain
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a different FN type in repeat with sequence similarities to repeats 5 or B.
Sriramarao and Bourdon (1993) have described the presence of an
additional FN type III repeat. The possibility that this repeat could be
responsible for the -490 bp band was not directly investigated, however,
several points indicate that this is probably not the case. Firstly the
molecular weight of a form containing repeats 5 and AD1 would only be
260 bp. Secondly Siri found that this repeat was either spliced out alone or
with repeats C and D, they never observed forms where it was included
alone. Their group also found that fibroblasts did not produce isoforms
containing this repeat, and as is described below ovarian fibroblasts do
produce the -490 bp form. The most convincing piece of evidence is that
the specific oligonucleotide B hybridises with this band, the sequence of
oligonucleotide B is not found in repeat AD1. It thus appears that the FN
type III repeat AD1 is not responsible for the -490 bp band, however, the
presence of this repeat may account for some of the other intermediate
forms, e.g. the -750 bp form, which were not described by Siri et al. (1991)
but were detected in the ovarian tumour samples.
Most other studies have demonstrated, using northern blotting
techniques, that the larger form of TN is preferentially expressed in
malignant tumours (Borsi et al., 1992). This larger form is generally
presumed to be the full length transcript of TN. Borsi et al. (1992) also
showed that carcinoma cell lines were capable of producing intermediate
molecular weight forms of TN. This could provide an explanation for the
obvious differences observed in this study, in the expression of
intermediate molecular weight RNA splice variants, between malignant
and benign ovarian tumours.
RT-PCR was used to detect TN RNA in samples of total cellular RNA
prepared from cell lines. The cells were cultured in medium containing
serum. Serum is a known inducer of TN synthesis, therefore this may
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account for discrepancies between the observations made on the levels of
"basal" TN protein expression and the detection of TN RNA. Cells were
cultured in serum containing media, as confluent cells were required for
efficient RNA extraction.
A panel of 9 ovarian carcinoma cell lines were examined and multiple
forms of TN RNA were detected in all these samples. The ovarian
fibroblasts PE012 and PE027 also demonstrated the presence of TN RNA.
Not all cell lines tested were positive for TN RNA, the breast carcinoma
cell lines ZR-75-1, T47D and MCF7 were negative.
It was observed that the fibroblasts produced a pattern of bands which was
very similar to that observed in the malignant tumour samples. This
provides further evidence to support the theory that the overexpression
of TN in malignant ovarian tumours may be due synthesis of the protein
by ovarian fibroblasts. Many of the bands observed in the carcinoma cell
line samples were not found in these primary tumours. This indicates
that while ovarian carcinoma cells are capable of synthesising TN RNA
they are not responsible for producing the RNA isoforms observed in the
malignant tumours. This may be because they may not have the correct
stimuli in vivo to produce TN.
Which of these RNA variants may result in the expression of proteins is
unknown and further studies would be required to characterise this.
While any internal alternative splicing should be capable of producing
TN protein it is possible that secondary structures of the RNA may differ
between isoforms resulting in some forms not being translated.
The staining observed in the sections of malignant tumours
demonstrated that all the TN was deposited within the stroma.
Experiments measuring the levels of TN secretion in cell lines indicated
that ovarian fibroblasts are probably the major source of this TN. It
should be noted that experiments in other cell types have demonstrated
that epithelial cells are capable of producing TN under certain
circumstances (Herlyn et al, 1991; Kawakatsu et al., 1992; Lightner et al.,
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1994). RT-PCR data indicates that the ovarian cell lines tested are capable
of producing multiple isoforms of TN RNA. However, within the
tumour samples examined no epithelial cell staining was observed; in
sections of breast tumours stained with the same antibody a small
number of tumours did show tumour cell staining, this phenomenon
has previously been demonstrated by Ishihara et al. (1995). The data
within this study suggests that fibroblasts are the major producers of TN
in ovarian tumours. The identity of the cell lines producing TN in
ovarian tumours could be definitively identified by in situ hybridisation.
Yoshida et al. (1995) proposed myofibroblasts as a candidate for the
producers of TN in breast tumour stroma. These cells resemble smooth
muscle cells rather than fibroblasts; fibroblasts cultured in the presence of
TGF-fi differentiate into myofibroblasts and concurrently begin to secrete
increased levels of TN.
The expression of TN is complicated by the fact that it can exist as
different isoforms. The specificity of the antibody, used in the
immunohistochemical studies and ELISA, is unknown. The antibody was
raised against TN secreted by the U251 glioma cell line, which is known to
secrete both large and small isoforms of TN, however, whether both
forms can be recognised by this antibody has not been reported. A study by
Zagzag et al. (1996) utilised the same monoclonal antibody to
immunoprecipitate TN, subsequent detection of the precipitated protein
used a different antibody, both large and small TN isoforms were detected
in the samples. While this experiment is still not absolute proof of the
specificity of the monoclonal antibody, the detection of both the large and
small isoforms implies that the monoclonal antibody used in their study,
and this thesis, can recognise both forms of the protein.
The possibility that the alternatively spliced isoforms of TN may have
different functions is discussed in section 6.4.
The existence of other TN family members has recently been discovered.
149
Again it is unknown whether this antibody cross reacts with other TN
proteins or is specific for TN-C. TN-R has not been identified in humans
and its distribution in chicken and rat is limited to the nervous system.
Human TN-X does have sections of homology with TN-C, however the
FN type HI repeats for example are more homologous to fibronectin than
to TN-C. TN-X also has a distribution pattern which is distinct and often
reciprocal to that of TN-C, although they are co-expressed in blood vessels
(Matsumoto et ah, 1994). The likelihood is that the antibody is specific,
and the protein detected in this study is TN-C.
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6.2 Control of tenascin secretion
In all the tumours examined, the immunoreactivity was strongest at
epithelial-mesenchymal junctions (as shown in figure 3.2). This
observation could have a number of different explanations: (1) the TN
may be accumulating in the basement membrane of these regions, as may
be expected with an ECM protein; (2) tumour cells could themselves be
producing the TN and depositing it in the matrix; or (3) the fibroblasts in
malignant tumours may be inherently different, from those in benign
tumours, in their capacity to express TN. The expression data from this
study of ovarian tumours and cell lines indicates that fibroblasts are likely
to be responsible for the synthesis of TN. Whether these fibroblasts from
malignant sources are inherently different was not investigated, however
this is unlikely, as the genetic changes producing the tumours examined
had occurred in the epithelial cells to produce an epithelial tumour.
Another explanation, with which this pattern is consistent, is the
hypothesis that TN expression is under paracrine control. The
investigations into general expression examined which cell types were
most likely to be responsible for the expression of TN in vivo.
Evidence for the paracrine stimulation of TN secretion has been
demonstrated in several tissues. In an elegant experiment Inaguma et al.
(1988) cultured embryonic mammary epithelium on an embryonic
mammary fat pad and observed a "halo" of TN around the growing
epithelium. Julian et al. (1994) noted a similar phenomenon in cultures
of uterine stroma and epithelia.
The experiments in this study, in which ovarian fibroblast and epithelial
cells were co-cultured maintained a physical separation of the two cell
types while allowing the circulation of any secreted factors. It was
observed that the mixed populations secreted increased amounts of TN.
These finding were consistent with the hypothesis that the expression of
TN is controlled by diffusible paracrine factors. These data agree with
findings by Chiquet-Ehrismann et al. (1989), who demonstrated that
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conditioned media from MCF-7 epithelial cells stimulated the production
of TN by fibroblasts.
6.2.1 Growth factor regulation of tenascin expression
A number of growth factors and cytokines and hormones have been
implicated in the control of TN, however, this is the first study to
examine potential modulating factors in ovarian systems. Initially the
immunohistochemical data from the malignant ovarian tumours was
examined to elucidate relationships between TN staining and the
expression of growth factors and steroid hormone receptors. Subsequent
experiments utilised cell lines in order to investigate, in vivo,
modulations by growth factors, hormones and cytokines.
The growth factor TGF-fi was one of the first modulators of TN to be
identified (Pearson et al., 1988). TGF-fi has been shown to play a role in
normal ovarian function, however little is known of the expression and
effects of TGF-fi in ovarian cancer (Bartlett et al., 1992). Data were
available on the expression of TGFfi mRNAs in a cohort of the ovarian
tumours used within this study, however there was no data on TGF-fi
protein. A significant positive correlation was found with TN protein
expression in the malignant tumours and expression of TGF-fii mRNA.
No correlation was observed with TGF-fi2 or £3. This is consistent with
findings made by Walker et al. (1994) in breast tumours, which
demonstrated a relationship between strong expression of TN and TGF-
fii, both measured immunohistochemically.
The relationship observed between strong TN staining and expression of
TGF-fii in the malignant tumours suggested that this growth factor plays
an important role in the regulation of TN production in ovarian cancer.
Further evidence for this theory was also provided by the dose dependent
induction of TN secretion in ovarian fibroblasts. The maximum
induction of TN was observed upon addition of 10 ng/ml TGF-fi 1. This
result was comparable to findings by Shrestha et ah, (1996), who also
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demonstrated a dose dependent induction of TN in mouse fibroblasts,
with the effect reaching a maximum at 10 ng/ml TGF-fii.
It has been demonstrated that the ovarian carcinoma cell line PEOl can
produce TGF-fii mRNA, however, whether these cells produce functional
TGF-fii protein has not been proven. This data indicates that one of the
factors responsible for the stimulation of TN secretion in co-culturing
experiments may be TGF-fii; this could be tested by using antibody to
neutralise TGF-fii in the medium, as described by Chiquet-Ehrismann et
al. (1989). There is also data to indicate that TGF-fii may alter the
proportions of different splice variants. Zhao and Young (1995),
demonstrated that TGF-fii preferentially stimulated the synthesis of the
smaller TN isoform in rat lung cells.
The relationship between TN staining in malignant tumours and the
expression mRNA for the growth factors EGF and TGF-a, or the EGF
receptor was investigated; no correlation with the level of TN staining
was observed. These factors were not investigated by
immunohistochemistry, the RT-PCR data on these factors was not
quantitative and investigations examining the level and location of
protein expression may have revealed a significant relationship.
The effects of a number of growth factors, hormones and cytokines were
examined in ovarian fibroblasts. The largest stimulation of TN secretion
in these cells was produced by TGF-fii,but IGF-II also produced a small yet
consistent increase in the levels of TN secreted by the ovarian fibroblasts.
TGF-a, IGF-I, endothelin and EGF were shown to have no effect on the
level of secretion from these cells. Interferon-y inhibited the secretion of
TN by the fibroblast cell line. This is in contrast to observations made by
Harkonen et al. (1995) who demonstrated induction of TN secretion by
interferon in lung epithelial cells. Effects of regulating factors on TN
secretion have been found to vary between different cell types (Rettig et
al., 1994) and interferon has been shown to inhibit the synthesis of other
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ECM molecules by fibroblasts (Yufit et al., 1995).
As with most other proteins which have been postulated to be "tumour
markers" once more detailed studies were undertaken, the distribution of
TN was found to be much more widespread than originally thought. In
normal tissues the expression of TN is highly regulated leading to its
restricted distribution pattern. The overexpression of TN in tumours is
likely to be due to the loss of this regulation, however it is also possible
that the malignant cells could be expressing the protein.
The high expression of TN at epithelial-mesenchymal junctions is
consistent with the paracrine induction of TN synthesis, experiments co-
culturing populations of fibroblasts and carcinoma cells indicated that a
paracrine loop exists in ovarian cell systems. The regulation of TN
synthesis, observed in normal tissues, is potentially overcome in
tumours by the constitutive overexpression of growth factors. Data has
shown that ovarian carcinoma cells can overexpress a number of
paracrine factors including TGF-13i (Bartlett et al., 1992). A potential model
of TN expression resulting from interactions between epithelial and
mesenchymal cells is illustrated in figure 6.1.
The TN promoter has been shown to have response elements which are
potential targets for transcription factors implicated in growth factor
signalling pathways, notably the phorbol ester response elements
TRE/AP-1 (Jones et ah, 1992). TGF-fi is known to act through transcription
factors capable of binding these sites (Barcellos-Hoff, 1993).
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6.2.2 Hormonal regulation of TN secretion
Addition of progesterone to ovarian fibroblasts produced a small but
consistent stimulation of TN secretion. The promoter of TN has been
studied (Jones et ah, 1990; Jones et ah, 1992; Gherzi et ah, 1995) but a
known hormone response element has not yet been identified; this
makes it a possibility that these hormones do not act directly upon the
promoter. An examination of oestrogen and progesterone receptor
expressed in the malignant ovarian tumours revealed that there was no
significant relationship between TN staining and the levels of these
receptors. It is possible that the increase in TN observed in the cultured
fibroblasts may be due to progesterone stimulating the production of
growth factors by the fibroblasts themselves resulting in an autocrine
stimulation of TN secretion. No stimulation of TN secretion by the
cultured fibroblasts was observed upon addition of oestrogen. The
gonadotrophins FSH and HCG inhibited the secretion of TN. These
hormonal modulations of TN secretion in fibroblast cells are surprising
as it is generally assumed that the targets of these hormones are ovarian
epithelial cells. However, the presence of progesterone receptor on
ovarian fibroblasts has been reported (Press and Greene, 1988).
Additionally, sections of ovarian tumours, stained for progesterone
receptor, were examined in the present study (data not shown); weak
nuclear staining was detected in the stromal tissue.
The pattern of expression observed by Tamura et al (1992) in normal
cycling ovaries, is consistent with the data in section 4.3.2. These data
demonstrated that TN secretion in ovarian fibroblasts can be influenced
by the hormones progesterone, follicle stimulating hormone and human
chorio gonadotrophin. Tamura et al found that expression of TN varied
according to the stage of the menstrual cycle. No significant TN staining
was observed in preovulatory follicles. In the early luteal phase, distinct
TN staining was seen at epithelial mesenchymal boundaries and during
involution of the corpora lutea diffuse TN staining was observed.
156
Tamura et al. (1992) suggest that these alterations in TN secretion are due
to stromal-parenchymal interactions. Their data is also consistent with
observations made in other hormone dependent tissues and data
presented within this study demonstrating that progesterone can
stimulate and FSH inhibit TN secretion, in ovarian fibroblasts. Therefore,
it is possible that the expression of TN in ovaries may also be regulated, in
part, in an endocrine manner. If the levels of the hormones progesterone
and FSH are plotted throughout the menstrual cycle it can be observed
that the peak in TN expression corresponds to the time of the cycle when
progesterone levels are high and FSH levels are low (figure 6.2).
Progesterone is produced by the corpus luteum and it was within
regressing corpus lutea that Tamura et al. (1992) observed the strongest
TN staining.
Further investigations of the hormonal control of TN, would be required
to confirm these theories; for example it would be of interest to observe
whether progesterone is capable of reversing the inhibition of TN
secretion produced by FSH, and time course experiments may provide
some indication of whether the hormonal control is direct or involves
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Figure 6.2 Simplified illustration of hormone levels and tenascin
expression in normal ovary
Mean plasma levels of FSH and progesterone were taken from Rang and
Dale (1991). Day 1 is the onset of menstruation and ovulation occurs on
day 14. The description of TN staining was adapted from Tamura et al.
(1993).
158
Ferguson et al. (1990) made similar observations regarding the variable
expression of TN in normal breast tissue throughout the menstrual cycle;
the peak in TN expression again coincides with the peak in progesterone
levels. It was also observed that TN levels in the uterus varied
throughout the menstrual cycle and in ovariectomized mice the
expression of TN was down regulated; the level could be restored by
progesterone but not oestrogen. This is compatible with the findings
reported here in ovarian fibroblasts, where a small induction of TN
secretion was observed upon addition of progesterone, while oestrogen
produced no effect on TN levels.
6.3 Functional properties of tenascin expression
The functions of TN in general are still the subject of much debate. The
protein has been demonstrated to influence many aspects of cells, effects
have often been shown to be contradictory and cell specific. This is the
first study to examine the interactions of TN with ovarian cell lines.
The reported functions of TN in other tissues and its overexpression in
malignant and highly invasive tumours has led to speculation that the
protein may be involved in the processes of invasion and metastasis. This
study examined the interactions of ovarian carcinoma cells with TN in
relation to two key components of the metastatic process; namely
adhesion and migration.
The use of adhesion assays demonstrated that TN promotes adhesion of
ovarian carcinoma cell lines to tissue culture plastics. Differences were
observed between the adherence of the cell lines to TN, compared with
fibronectin and collagen IV. SKOV-3 and 59M cells attached to TN at a
lower level than collagen IV and fibronectin. PEOl cells attached more
strongly to TN than to collagen IV, and PE04, which showed a
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preferential level of attachment to TN than fibronectin. Further studies
should examine the interaction of TN with the other ECM proteins in
particular fibronectin. TN has been shown to interfere with the cell
binding properties of fibronectin (Chiquet-Ehrismann et al., 1988); this
may be through competition for cellular receptors.
Berens et al. (1996) observed that adhesion of glioma cells to TN increased
to a maximum level at 10jig/ml of protein, but adhesion decreased at
concentrations of 33 and 100 pg/ml. Experiments in this study with
SKOV-3 cells demonstrated that adhesion to TN did increase to a
maximum at 10 pg/ml, however it was observed that the level of
adhesion plateaued and no decline was noted in this cell line even when
taken out to 40 pg/ml.
Observations made by examining the cells under phase contrast
microscopy were generally consistent, in terms of apparent levels of
attachment, with the quantitative measurements. The majority of other
studies of epithelial cells have demonstrated that TN inhibits cell
spreading and most cells have a more rounded morphology when
compared with their appearance on other ECM substrates (Kawakatsu et
al., 1992). Within this study examination of PE04 and PEOl cells revealed
that they did not spread on TN and remained rounded; no such marked
differences were observed with the 59M cell line.
The observation of the SKOV-3 cell line demonstrated that the cells
adopted a "spindly" appearance on TN, with the apparent formation of
dendritic projections. This can be compared to the study by Canfield and
Schor (1995); they demonstrated that TN mediated the "sprouting" of
endothelial cells. Endothelial cells which are forming projections are
more angiogenic. These sprouting cells are very similar in appearance to
the SKOV-3 cells cultured on TN. Whether this morphological difference
is implicated in the invasive behaviour of SKOV-3 remains to be
elucidated; matrigel based invasion assays would provide a useful tool for
further studies.
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Examination of the effects of TN on migration demonstrated that TN
promotes the migration of the SKOV-3 cell line over the level observed
on BSA, however the level of motility on TN did not appear to be as large
as it was on fibronectin. An experiment using the PEOl cell line indicated
that TN and fibronectin were also able to promote cell migration, and in
this instance the level of migration on TN was greater on TN than
fibronectin. Migration was assayed on a single concentration of TN
(10 |ig/ml), and therefore these data cannot be directly compared with
those observations made by Berens et al. (1996). They observed the
migration of glioma cells on TN and found levels increased on 1 and 3
pg/ml TN but migration was actively suppressed on 30 or 100 (ig/ml TN.
Other reports indicate that TN can affect cell motility and migration in
vivo; for example the expression of the large TN variant correlates with
cell migration in the developing cornea (Kaplony et al., 1991). It has also
been shown that TN inhibits migration of mesodermal cells during
amphibian embryo gastrulation (Riou et al., 1990)
TN has been demonstrated to interact with a number of integrins
(Yokosaki and Sheppard, 1995). The expression of cellular adhesion
molecules in ovarian cancer, such as integrins, have not been extensively
studied. A recent study (Bridges et al., 1995) demonstrated that in ovarian
tumours there was an apparent up regulation of fil and a2 integrins
while there was a loss of al chains. Gardner et al. (1995) examined the
expression of fil, fi2, fi3 and a4 integrins in a panel of 13 ovarian tumour
cell lines (not including any of the lines in this study). They found that fil
and fi3 integrins were expressed at high levels on the majority of these
cell lines.
The flow cytometric analysis of integrins in this study, demonstrated that
all of the cell lines expressed the a2fil integrin which is capable of binding
to TN (Sriramarao et al., 1993). The SKOV-3 cell line also expressed the
integrin aVfi3, this integrin has been shown to be capable of interacting
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with TN (Sriramarao et al., 1993) and is strongly implicated in the
malignant behaviour of melanoma (Seftor et al., 1992) and glioblastoma
(Gladson and Cheresh, 1994). Seftor et al. (1992) demonstrated that
activation of the aVC3 integrin resulted in enhanced invasiveness of
melanoma cells. Berens et al. (1996) demonstrated that adhesion to TN
could be blocked with anti-fil antibodies but was enhanced by incubation
with anti-63 antibody.
Ramos et al. (1996) demonstrated that the integrin aV£6 is induced in
squamous cell carcinoma and this integrin appeared to be preferentially
expressed on poorly invasive cells. None of the cell lines examined in
this study expressed this integrin, which has also been shown to be
capable of binding TN. Carreiras et al. (1995) also demonstrated that the
ovarian carcinoma cell line IGROV-1 did not express aVfi6 but did
express a2fil and aVfi3.
Other integrins have been shown to interact with TN, antibodies were
not available to these proteins It is therefore possible that the ovarian cell
lines may express any of these integrins in addition to those identified.
The experiments carried out on the PEOl ovarian carcinoma cell line
demonstrated that TN, at levels secreted by fibroblast cells, did not
stimulate the growth of these cells. Adhesion assays and analysis of the
integrin receptors indicated that these cells were capable of interacting
with TN. This suggests that in ovarian systems TN may not play a
significant role in proliferation and its function may be associated more
with the invasive aspect of ovarian cancer.
Other studies, however, have shown that TN can stimulate the growth of
quiescent mouse fibroblasts and conversely inhibit the growth of the
epidermal cell line Pam212 (End et al., 1992). In another study Crossin
(1991) demonstrated that TN inhibited the growth of stimulated fibroblast
cells. Although it has been speculated that the mitogenic effect of TN may
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be due to contamination with growth factors, End et al. (1992)
demonstrated that there was no increase in tyrosine phosphorylation
upon addition of the TN, thus making it unlikely that a contaminating
growth factor was responsible.
It has been demonstrated that TN expression is cell cycle dependent with
a marked increase in synthesis and accumulation of the larger isoform of
TN at the transition from Go to Gi (Borsi et al., 1994). This change in
distribution of isoforms suggests that the two main isoforms may play
different roles in cellular proliferation, potentially through modulating
the level of cellular attachment to the substrate. However experiments
carried out using different fragments of TN (End et al., 1992)
demonstrated that while the mitogenic activity was located within the FN
type III repeats, both the splice variants tested could stimulate growth
indicating that the mitogenic signal was not located in the alternatively
spliced segments. These fragments were added to the media and it is
possible that different isoforms may produce differing effects when they
are part of the matrix.
The fact that different isoforms may posses different functions could
explain the contrary results on proliferation, as both End and Crossin
used different sources of TN to this study, and the discrepancies noted
could be due to different isoform compositions of the TN sources used.
However it is also probable that TN may exert differing effects on
different cell types, as the protein has been shown to interact with a
number of different receptors, the effects and expression of which may
also vary.
6.4 The role of tenascin in ovarian cancer
It has been hypothesised that proteins may be expressed superfluously in
tissues where they are non-functional, thus Erickson (1993) speculates
that the high levels of TN observed in, for example healing wounds, may
simply be an accident of gene regulation, tolerated because TN is an
innocuous molecule in these situations. This study however provides
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evidence that TN is capable of interacting with tumour cells, to promote
adhesion, migration and alter cell morphology. These interactions imply
that TN is a protein involved in the process of cancer progression. Its
actual role in ovarian cancer can be speculated upon, from the data
presented within this thesis.
The overexpression of TN in malignant tumours results in a stroma with
a different composition of ECM proteins to that observed in benign
tumours and normal ovary. The pattern of expression observed in the
malignant tumours does, however, resemble that described by Tamura et
al. (1992), who described a stronger, more diffuse expression of TN during
regression of the corpora lutea. In normal ovary this stromal expression is
transient and limited to the time of tissue reorganisation. The
inappropriate expression of TN in the stroma of malignant tumours
implies that it may be involved in the "reorganisation " of the tumour
and its surrounding stroma, which results in the movement of the
tumour cells from their original site.
Yoshida et al. (1995) speculated that TN may be capable of both promoting
cancer cell invasion and protecting against invasion. In breast cancer high
levels of TN expression have been found to correlate with poor prognosis
(Ishihara et al., 1995). This may be explained by the anti-adhesive
properties of TN; helping cells detach from their substrate, decreasing
focal adhesion and promoting migration. Conversely, in colon cancer it
has been observed that high levels of TN in tumours results in lower
levels of metastasis (Sugawara et al., 1993). This protective effect may be
due to TN creating a barrier around the malignant cells which they can
not attach to.
These studies of ovarian cancer have revealed that there is
overexpression of TN in malignant ovarian tumours. No relationship
was observed between the degree of TN expression and clinical stage.
Whilst clinical stage indicates the spread of the disease, all malignant
tumours, by definition, are invasive. It is therefore unclear from this data
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whether TN may be promoting or protecting against invasion in ovarian
cancer. It was noted that whilst borderline tumours often expressed
diffuse stromal TN, the intensity of staining was lower than that observed
in malignant tumours. Borderline tumours have low metastatic potential
and the fact that they demonstrate a level of staining which could be
considered intermediate between benign and malignant suggests that the
expression of TN increases in more invasive tumours.
The interaction of ovarian carcinoma cell lines with TN demonstrated
that adhesion and migration were promoted by TN. The level of
adhesion was generally less than that observed on other ECM molecules
and it has been hypothesised that an intermediate level of adhesion
facilitates invasion (Aznavoorian et al., 1992). The isoform of TN used in
the functional assays was one whose size indicates that it contains the
alternatively spliced region. Different isoforms of TN have been shown to
possess different properties, as is discussed below.
The present study has indicated, by RT-PCR data that different isoforms of
TN are expressed in malignant and benign/normal ovarian tissues. The
existence of multiple TN isoforms, may in part explain the different and
often contradictory results observed in studies of TN function. Differences
in biological function between TN isoforms have been reported. Chiquet-
Ehrismann et al. (1991) reported that the smaller isoform of TN
preferentially bound to fibronectin, this is consistent with the finding that
the smaller form of TN is better incorporated into the matrix. The smaller
form of TN, found in normal and benign situations, is likely to be
incorporated into the matrix close to its site of production resulting in
focal immunostaining. Larger isoforms do not bind fibronectin and are
not efficiently incorporated into the matrix, therefore they may diffuse
from their site of production. This observation may partly explain the
distribution pattern of TN observed in malignant and benign tumours.
The contrary functions of TN, with regards to cell adhesion, were first
investigated by Spring et al. (1989), who utilised recombinant TN
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fragments. They demonstrated that TN contained both adhesive (within
the alternatively spliced region) and anti-adhesive (within the EGF-like
repeats) sites. Subsequent studies have identified at least four non-
overlapping sites on TN have been shown to interact with the cell surface
(Prieto et al., 1992).
The priorities of any future work would therefore be to define the protein
expression of the different TN isoforms in ovarian tumours and cell
lines, in order to elucidate further the role TN plays in ovarian cancer.
6.5 Summary
Work presented within this thesis has demonstrated that there is
overexpression of TN in malignant ovarian tumours, however, the
protein can still be observed in normal ovarian tissue. The cellular source
of TN in these tumours is likely to be fibroblast cells, as indicated by the
levels of TN expressed by these cell types in culture, and the similarity of
their TN RNA expression pattern to malignant tumours. Whether the
protein expressed in the malignant situation is a different isoform was
not determined, however RT-PCR data suggested that malignant
tumours were capable of producing RNA splice variants of a different
molecular weight to those found in normal or benign situations. The
possibility of utilising an anti-TN antibody to deliver radiation or
cytotoxic compounds to ovarian tumours, would rely on this differential
expression of different TN protein isoforms in normal and malignant
ovarian tissue. The expression of different TN isoforms in the matrix
may also determine the role of this protein in ovarian cancer.
Evidence from in vitro experiments demonstrated that the synthesis of
TN is under paracrine control. TN was induced in fibroblasts by soluble
factors. TGF-fii produced a large stimulation of TN secretion in
fibroblasts. mRNA for this growth factor is expressed by ovarian
carcinoma cells and its expression in tumours correlated with the degree
of TN staining; these data implicate TGF-fii as an important regulator of
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TN in ovarian cancer.
Investigation of the interaction of ovarian carcinoma cells with TN
revealed that TN could promote the adhesion and migration of these
cells, yet probably was not involved in altering the growth rate. This
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